0001599117 false --12-31 Q3 0001599117
2021-01-01 2021-09-30 0001599117 2021-11-12 0001599117 2021-09-30
0001599117 2020-12-31 0001599117 2021-07-01 2021-09-30 0001599117
2020-07-01 2020-09-30 0001599117 2020-01-01 2020-09-30 0001599117
us-gaap:ServiceMember 2021-07-01 2021-09-30 0001599117
us-gaap:ServiceMember 2020-07-01 2020-09-30 0001599117
us-gaap:ServiceMember 2021-01-01 2021-09-30 0001599117
us-gaap:ServiceMember 2020-01-01 2020-09-30 0001599117
MNTR:FinanceLeaseRevenueMember 2021-07-01 2021-09-30 0001599117
MNTR:FinanceLeaseRevenueMember 2020-07-01 2020-09-30 0001599117
MNTR:FinanceLeaseRevenueMember 2021-01-01 2021-09-30 0001599117
MNTR:FinanceLeaseRevenueMember 2020-01-01 2020-09-30 0001599117
us-gaap:PreferredStockMember 2021-06-30 0001599117
us-gaap:CommonStockMember 2021-06-30 0001599117
us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001599117
us-gaap:RetainedEarningsMember 2021-06-30 0001599117
us-gaap:ParentMember 2021-06-30 0001599117
us-gaap:NoncontrollingInterestMember 2021-06-30 0001599117
2021-06-30 0001599117 us-gaap:PreferredStockMember 2021-07-01
2021-09-30 0001599117 us-gaap:CommonStockMember 2021-07-01
2021-09-30 0001599117 us-gaap:AdditionalPaidInCapitalMember
2021-07-01 2021-09-30 0001599117 us-gaap:RetainedEarningsMember
2021-07-01 2021-09-30 0001599117 us-gaap:ParentMember 2021-07-01
2021-09-30 0001599117 us-gaap:NoncontrollingInterestMember
2021-07-01 2021-09-30 0001599117 us-gaap:PreferredStockMember
2021-09-30 0001599117 us-gaap:CommonStockMember 2021-09-30
0001599117 us-gaap:AdditionalPaidInCapitalMember 2021-09-30
0001599117 us-gaap:RetainedEarningsMember 2021-09-30 0001599117
us-gaap:ParentMember 2021-09-30 0001599117
us-gaap:NoncontrollingInterestMember 2021-09-30 0001599117
us-gaap:PreferredStockMember 2020-06-30 0001599117
us-gaap:CommonStockMember 2020-06-30 0001599117
us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001599117
us-gaap:RetainedEarningsMember 2020-06-30 0001599117
us-gaap:ParentMember 2020-06-30 0001599117
us-gaap:NoncontrollingInterestMember 2020-06-30 0001599117
2020-06-30 0001599117 us-gaap:PreferredStockMember 2020-07-01
2020-09-30 0001599117 us-gaap:CommonStockMember 2020-07-01
2020-09-30 0001599117 us-gaap:AdditionalPaidInCapitalMember
2020-07-01 2020-09-30 0001599117 us-gaap:RetainedEarningsMember
2020-07-01 2020-09-30 0001599117 us-gaap:ParentMember 2020-07-01
2020-09-30 0001599117 us-gaap:NoncontrollingInterestMember
2020-07-01 2020-09-30 0001599117 us-gaap:PreferredStockMember
2020-09-30 0001599117 us-gaap:CommonStockMember 2020-09-30
0001599117 us-gaap:AdditionalPaidInCapitalMember 2020-09-30
0001599117 us-gaap:RetainedEarningsMember 2020-09-30 0001599117
us-gaap:ParentMember 2020-09-30 0001599117
us-gaap:NoncontrollingInterestMember 2020-09-30 0001599117
2020-09-30 0001599117 us-gaap:PreferredStockMember 2020-12-31
0001599117 us-gaap:CommonStockMember 2020-12-31 0001599117
us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001599117
us-gaap:RetainedEarningsMember 2020-12-31 0001599117
us-gaap:ParentMember 2020-12-31 0001599117
us-gaap:NoncontrollingInterestMember 2020-12-31 0001599117
us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001599117
us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001599117
us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30
0001599117 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30
0001599117 us-gaap:ParentMember 2021-01-01 2021-09-30 0001599117
us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30
0001599117 us-gaap:PreferredStockMember 2019-12-31 0001599117
us-gaap:CommonStockMember 2019-12-31 0001599117
us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001599117
us-gaap:RetainedEarningsMember 2019-12-31 0001599117
us-gaap:ParentMember 2019-12-31 0001599117
us-gaap:NoncontrollingInterestMember 2019-12-31 0001599117
2019-12-31 0001599117 us-gaap:PreferredStockMember 2020-01-01
2020-09-30 0001599117 us-gaap:CommonStockMember 2020-01-01
2020-09-30 0001599117 us-gaap:AdditionalPaidInCapitalMember
2020-01-01 2020-09-30 0001599117 us-gaap:RetainedEarningsMember
2020-01-01 2020-09-30 0001599117 us-gaap:ParentMember 2020-01-01
2020-09-30 0001599117 us-gaap:NoncontrollingInterestMember
2020-01-01 2020-09-30 0001599117 MNTR:WasteConsolidatorsIncMember
2021-09-30 0001599117 MNTR:MentorIPLLCMember 2016-04-18 0001599117
MNTR:MentorIPLLCMember MNTR:LarsonAndLarsonCapitalLLCMember
2016-04-18 0001599117 MNTR:MentorIPLLCMember us-gaap:NonUsMember
2016-04-18 0001599117 MNTR:MentorIPLLCMember
MNTR:LarsonAndLarsonCapitalLLCMember us-gaap:NonUsMember 2016-04-18
0001599117 MNTR:PartnerOneMember 2018-12-31 0001599117
MNTR:PartnerTwoMember 2018-02-08 0001599117 MNTR:PartnerTwoMember
2019-03-11 2019-03-12 0001599117 2020-01-01 2020-12-31 0001599117
2019-01-01 2019-12-31 0001599117 MNTR:ElectrumPartnersLLCMember
MNTR:SecuredCapitalAgreementMember 2018-10-31 0001599117
MNTR:ElectrumPartnersLLCMember
MNTR:SecondSecuredCapitalAgreementMember 2019-01-28 0001599117
MNTR:CapitalAgreementMember 2019-01-28 0001599117
us-gaap:SubsequentEventMember MNTR:MentorIPLLCMember 2021-10-06
0001599117 MNTR:NeuCourtIncMember 2018-12-01 2018-12-31 0001599117
MNTR:NeuCourtIncMember 2021-01-01 2021-09-30 0001599117
MNTR:NeuCourtIncMember 2021-09-30 0001599117 MNTR:NeuCourtIncMember
2020-12-31 0001599117 MNTR:WasteConsolidatorsIncMember 2013-12-31
2014-01-01 0001599117 MNTR:WasteConsolidatorsIncMember 1999-01-01
1999-12-31 0001599117 MNTR:WasteConsolidatorsIncMember 1999-12-31
0001599117 2015-04-10 0001599117 2015-04-09 2015-04-10 0001599117
MNTR:VehicleFleetMember 2021-09-30 0001599117
MNTR:VehicleFleetMember 2020-12-31 0001599117
MNTR:OperatingAgreementsMember 2021-07-01 2021-09-30 0001599117
MNTR:OperatingAgreementsMember 2020-07-01 2020-09-30 0001599117
MNTR:OperatingAgreementsMember 2021-01-01 2021-09-30 0001599117
MNTR:OperatingAgreementsMember 2020-01-01 2020-09-30 0001599117
MNTR:ConvertibleNotesReceivableOneMember MNTR:NeuCourtIncMember
2021-09-30 0001599117 MNTR:ConvertibleNotesReceivableOneMember
MNTR:NeuCourtIncMember 2020-12-31 0001599117
MNTR:NovemberTwentyTwoTwoThousandSeventeenMember
MNTR:ConvertibleNotesReceivableMember MNTR:NeuCourtIncMember
2021-09-30 0001599117
MNTR:NovemberTwentyTwoTwoThousandSeventeenMember
MNTR:ConvertibleNotesReceivableMember MNTR:NeuCourtIncMember
2020-12-31 0001599117 MNTR:ConvertibleNotesReceivableMember
MNTR:NovemberTwentyTwoTwoThousandSeventeenMember
MNTR:NeuCourtIncMember 2021-01-01 2021-09-30 0001599117
MNTR:ConvertibleNotesReceivableMember
MNTR:NovemberTwentyTwoTwoThousandSeventeenMember
MNTR:NeuCourtIncMember 2019-11-02 2019-11-04 0001599117
MNTR:ConvertibleNotesReceivableMember
MNTR:NovemberTwentyTwoTwoThousandSeventeenMember
MNTR:NeuCourtIncMember 2021-06-30 0001599117
MNTR:ConvertibleNotesReceivableTwoMember MNTR:NeuCourtIncMember
2021-09-30 0001599117 MNTR:ConvertibleNotesReceivableTwoMember
MNTR:NeuCourtIncMember 2020-12-31 0001599117
MNTR:OctoberThirtyOneTwoThousandEighteenMember
MNTR:ConvertibleNotesReceivableMember MNTR:NeuCourtIncMember
2021-09-30 0001599117
MNTR:OctoberThirtyOneTwoThousandEighteenMember
MNTR:ConvertibleNotesReceivableMember MNTR:NeuCourtIncMember
2020-12-31 0001599117 MNTR:ConvertibleNotesReceivableMember
MNTR:OctoberThirtyOneTwoThousandEighteenMember
MNTR:NeuCourtIncMember 2021-01-01 2021-09-30 0001599117
MNTR:ConvertibleNotesReceivableMember MNTR:NeuCourtIncMember
2021-09-30 0001599117 MNTR:ConvertibleNotesReceivableMember
MNTR:NeuCourtIncMember 2020-12-31 0001599117
MNTR:ConvertibleNotesReceivableMember MNTR:NeuCourtIncMember
2021-01-01 2021-09-30 0001599117
MNTR:ConvertibleNotesReceivableMember MNTR:NeuCourtIncMember
2021-01-01 2021-06-30 0001599117
MNTR:ConvertibleNotesReceivableMember
MNTR:TwoThousandSeventeenNotesMember 2021-01-01 2021-09-30
0001599117 MNTR:ConvertibleNotesReceivableMember
MNTR:TwoThousandEighteenNotesMember 2021-01-01 2021-09-30
0001599117 MNTR:PartnerTwoMember 2021-07-01 2021-09-30 0001599117
MNTR:PartnerTwoMember 2020-07-01 2020-09-30 0001599117
MNTR:PartnerTwoMember 2021-01-01 2021-09-30 0001599117
MNTR:PartnerTwoMember 2020-01-01 2020-09-30 0001599117
MNTR:RecoveryPurchaseAgreementMember MNTR:ElectrumMember 2018-10-30
0001599117 MNTR:RecoveryPurchaseAgreementMember MNTR:ElectrumMember
2021-09-30 0001599117 MNTR:RecoveryPurchaseAgreementMember
MNTR:ElectrumMember 2020-12-31 0001599117
us-gaap:SubsequentEventMember MNTR:ElectrumMember 2021-10-01
2021-11-09 0001599117 MNTR:ElectrumMember
MNTR:SecuredCaptialAgreementMember 2018-10-29 2018-10-31 0001599117
MNTR:SecuredCaptialAgreementMember MNTR:ElectrumMember 2021-09-30
0001599117 MNTR:SecuredCaptialAgreementMember MNTR:ElectrumMember
2020-12-31 0001599117 MNTR:SecondSecuredCaptialAgreementMember
2021-09-30 0001599117 MNTR:ElectrumMember
MNTR:SecondSecuredCaptialAgreementMember 2018-10-29 2018-10-31
0001599117 MNTR:SecondSecuredCaptialAgreementMember
MNTR:ElectrumMember 2021-09-30 0001599117
MNTR:SecondSecuredCaptialAgreementMember MNTR:ElectrumMember
2020-12-31 0001599117 MNTR:RecoveryPurchaseAgreementMember
2021-09-30 0001599117 MNTR:RecoveryPurchaseAgreementMember
2020-12-31 0001599117 MNTR:SecuredCaptialAgreementMember 2021-09-30
0001599117 MNTR:SecuredCaptialAgreementMember 2020-12-31 0001599117
MNTR:SecondSecuredCaptialAgreementMember 2020-12-31 0001599117
us-gaap:SecuritiesAssetsMember us-gaap:FairValueInputsLevel1Member
2019-12-31 0001599117 us-gaap:FairValueInputsLevel2Member
2019-12-31 0001599117
MNTR:ContractualInterestsInLegalRecoveriesMember
us-gaap:FairValueInputsLevel3Member 2019-12-31 0001599117
MNTR:InvestmentInCommonStockWarrantsMember
us-gaap:FairValueInputsLevel3Member 2019-12-31 0001599117
MNTR:OtherEquityInvestmentsMember
us-gaap:FairValueInputsLevel3Member 2019-12-31 0001599117
us-gaap:SecuritiesAssetsMember us-gaap:FairValueInputsLevel1Member
2020-01-01 2020-12-31 0001599117
us-gaap:FairValueInputsLevel2Member 2020-01-01 2020-12-31
0001599117 MNTR:ContractualInterestsInLegalRecoveriesMember
us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31
0001599117 MNTR:InvestmentInCommonStockWarrantsMember
us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31
0001599117 MNTR:OtherEquityInvestmentsMember
us-gaap:FairValueInputsLevel3Member 2020-01-01 2020-12-31
0001599117 us-gaap:SecuritiesAssetsMember
us-gaap:FairValueInputsLevel1Member 2020-12-31 0001599117
us-gaap:FairValueInputsLevel2Member 2020-12-31 0001599117
MNTR:ContractualInterestsInLegalRecoveriesMember
us-gaap:FairValueInputsLevel3Member 2020-12-31 0001599117
MNTR:InvestmentInCommonStockWarrantsMember
us-gaap:FairValueInputsLevel3Member 2020-12-31 0001599117
MNTR:OtherEquityInvestmentsMember
us-gaap:FairValueInputsLevel3Member 2020-12-31 0001599117
us-gaap:SecuritiesAssetsMember us-gaap:FairValueInputsLevel1Member
2021-01-01 2021-09-30 0001599117
us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-09-30
0001599117 MNTR:ContractualInterestsInLegalRecoveriesMember
us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30
0001599117 MNTR:InvestmentInCommonStockWarrantsMember
us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30
0001599117 MNTR:OtherEquityInvestmentsMember
us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-09-30
0001599117 us-gaap:SecuritiesAssetsMember
us-gaap:FairValueInputsLevel1Member 2021-09-30 0001599117
us-gaap:FairValueInputsLevel2Member 2021-09-30 0001599117
MNTR:ContractualInterestsInLegalRecoveriesMember
us-gaap:FairValueInputsLevel3Member 2021-09-30 0001599117
MNTR:InvestmentInCommonStockWarrantsMember
us-gaap:FairValueInputsLevel3Member 2021-09-30 0001599117
MNTR:OtherEquityInvestmentsMember
us-gaap:FairValueInputsLevel3Member 2021-09-30 0001599117
us-gaap:EquitySecuritiesMember 2021-09-30 0001599117
us-gaap:EquitySecuritiesMember 2021-01-01 2021-09-30 0001599117
MNTR:SeriesBCommonStockWarrantsMember 2021-09-30 0001599117
MNTR:SeriesDCommonStockWarrantsMember 2021-09-30 0001599117
MNTR:SeriesHWarrantsMember 2021-09-30 0001599117
MNTR:SeriesBCommonStockWarrantsMember 2019-12-31 0001599117
MNTR:SeriesDCommonStockWarrantsMember 2019-12-31 0001599117
MNTR:SeriesBAndDCommonStockWarrantsMember 2019-12-31 0001599117
MNTR:SeriesBCommonStockWarrantsMember 2020-01-01 2020-12-31
0001599117 MNTR:SeriesDCommonStockWarrantsMember 2020-01-01
2020-12-31 0001599117 MNTR:SeriesBAndDCommonStockWarrantsMember
2020-01-01 2020-12-31 0001599117
MNTR:SeriesBCommonStockWarrantsMember 2020-12-31 0001599117
MNTR:SeriesDCommonStockWarrantsMember 2020-12-31 0001599117
MNTR:SeriesBAndDCommonStockWarrantsMember 2020-12-31 0001599117
MNTR:SeriesBCommonStockWarrantsMember 2021-01-01 2021-09-30
0001599117 MNTR:SeriesDCommonStockWarrantsMember 2021-01-01
2021-09-30 0001599117 MNTR:SeriesBAndDCommonStockWarrantsMember
2021-01-01 2021-09-30 0001599117
MNTR:SeriesBAndDCommonStockWarrantsMember 2021-09-30 0001599117
MNTR:SeriesHWarrantsMember 2019-12-31 0001599117
MNTR:SeriesHWarrantsMember 2020-01-01 2020-12-31 0001599117
MNTR:SeriesHWarrantsMember 2020-12-31 0001599117
MNTR:SeriesHWarrantsMember 2021-01-01 2021-09-30 0001599117
MNTR:ChetBillingsleyCEOMember MNTR:SeriesBCommonStockWarrantsMember
2021-09-30 0001599117 2014-08-06 2014-08-08 0001599117
MNTR:SeriesQPreferredStockMember 2021-09-30 0001599117
MNTR:SeriesQPreferredStockMember 2018-05-29 2018-05-30 0001599117
MNTR:SeriesQPreferredStockMember 2018-05-30 0001599117
MNTR:SeriesQPreferredStockMember 2021-12-31 0001599117
MNTR:SeriesQPreferredStockMember 2020-12-31 0001599117
us-gaap:LoansPayableMember 2021-01-01 2021-09-30 0001599117
MNTR:LoansPayableOneMember 2021-01-01 2021-09-30 0001599117
MNTR:RepublicBankOfArizonaMember 2020-12-31 0001599117
MNTR:BankOfSouthernCaliforniaMember 2020-12-31 0001599117
MNTR:WasteConsolidatorsIncMember 2020-11-30 0001599117
MNTR:WasteConsolidatorsIncMember 2021-01-01 2021-09-30 0001599117
MNTR:SecondPaycheckProtectionProgramLoanMember 2021-02-17
0001599117 MNTR:PaycheckProtectionProgramMember
MNTR:BankOfArizonaMember 2021-09-30 0001599117
MNTR:PaycheckProtectionProgramMember MNTR:BankOfArizonaMember
2020-12-31 0001599117 MNTR:PaycheckProtectionProgramMember
2021-01-01 2021-09-30 0001599117
MNTR:PaycheckProtectionProgramMember MNTR:BankOfSouthernMember
2021-09-30 0001599117 MNTR:PaycheckProtectionProgramMember
MNTR:BankOfSouthernMember 2020-12-31 0001599117
MNTR:SecondPaycheckProtectionProgramMember 2021-01-01 2021-09-30
0001599117 MNTR:PaycheckProtectionProgramMember 2021-09-30
0001599117 MNTR:PaycheckProtectionProgramMember 2020-12-31
0001599117 MNTR:PaycheckProtectionProgramMember 2021-07-01
2021-09-30 0001599117 MNTR:PaycheckProtectionProgramMember
2020-07-01 2020-09-30 0001599117
MNTR:PaycheckProtectionProgramMember 2021-01-01 2021-09-30
0001599117 MNTR:PaycheckProtectionProgramMember 2020-01-01
2020-09-30 0001599117 MNTR:EconomicInjuryDisasterLoanMember
2020-07-07 2020-07-09 0001599117
MNTR:EconomicInjuryDisasterLoanMember 2020-07-09 0001599117
2020-07-07 2020-07-09 0001599117 MNTR:WasteConsolidatorsIncMember
2021-09-30 0001599117 MNTR:WasteConsolidatorsIncMember 2020-12-31
0001599117 MNTR:WasteConsolidatorsIncMember 2020-01-01 2020-12-31
0001599117 MNTR:EconomicInjuryDisasterLoanAdvanceMember 2021-07-01
2021-09-30 0001599117 MNTR:EconomicInjuryDisasterLoanAdvanceMember
2020-07-01 2020-09-30 0001599117
MNTR:EconomicInjuryDisasterLoanAdvanceMember 2021-01-01 2021-09-30
0001599117 MNTR:EconomicInjuryDisasterLoanAdvanceMember 2020-01-01
2020-09-30 0001599117 1998-12-09 0001599117 srt:MaximumMember
2021-01-01 2021-09-30 0001599117 srt:MaximumMember 2021-09-30
0001599117 MNTR:WasteConsolidatorsIncMember 2020-12-15 0001599117
MNTR:MentorCapitalIncCEOMember 2021-03-11 2021-03-12 0001599117
MNTR:MentorCapitalIncCEOMember 2021-03-12 0001599117
MNTR:MentorCapitalIncCEOMember 2021-06-16 2021-06-17 0001599117
MNTR:NotesPurchaseAgreementMember MNTR:GFarmaLabsLimitedMember
2017-03-16 2017-03-17 0001599117 MNTR:SecuredPromissoryNotesMember
MNTR:NotesPurchaseAgreementMember MNTR:GFarmaLabsLimitedMember
2017-03-16 2017-03-17 0001599117 MNTR:SecuredPromissoryNotesMember
MNTR:NotesPurchaseAgreementMember MNTR:GFarmaLabsLimitedMember
2017-03-17 0001599117 MNTR:GFarmaLabsLimitedMember
MNTR:EquityPurchaseAndIssuanceAgreementMember 2018-09-06 0001599117
MNTR:GFarmaLabsLimitedMember 2018-09-05 2018-09-06 0001599117
MNTR:GFarmaLabsLimitedMember 2020-06-30 0001599117
MNTR:GFarmaLabsLimitedMember 2021-04-01 2021-06-30 0001599117
MNTR:SettlementAgreementAndMutualReleaseMember MNTR:GFarmaMember
2021-08-26 2021-08-27 0001599117
MNTR:SettlementAgreementAndMutualReleaseMember MNTR:GFarmaMember
2021-08-27 0001599117 MNTR:CannabisAndMedicalMarijuanaSegmentMember
2021-07-01 2021-09-30 0001599117
MNTR:FacilityOperationsRelatedMember 2021-07-01 2021-09-30
0001599117 MNTR:CorporateAndEliminationsMember 2021-07-01
2021-09-30 0001599117 MNTR:ConsolidatedMember 2021-07-01 2021-09-30
0001599117 MNTR:CannabisAndMedicalMarijuanaSegmentMember 2020-07-01
2020-09-30 0001599117 MNTR:FacilityOperationsRelatedMember
2020-07-01 2020-09-30 0001599117
MNTR:CorporateAndEliminationsMember 2020-07-01 2020-09-30
0001599117 MNTR:ConsolidatedMember 2020-07-01 2020-09-30 0001599117
MNTR:CannabisAndMedicalMarijuanaSegmentMember 2021-01-01 2021-09-30
0001599117 MNTR:FacilityOperationsRelatedMember 2021-01-01
2021-09-30 0001599117 MNTR:CorporateAndEliminationsMember
2021-01-01 2021-09-30 0001599117 MNTR:ConsolidatedMember 2021-01-01
2021-09-30 0001599117 MNTR:CannabisAndMedicalMarijuanaSegmentMember
2021-09-30 0001599117 MNTR:FacilityOperationsRelatedMember
2021-09-30 0001599117 MNTR:CorporateAndEliminationsMember
2021-09-30 0001599117 MNTR:ConsolidatedMember 2021-09-30 0001599117
MNTR:CannabisAndMedicalMarijuanaSegmentMember 2020-01-01 2020-09-30
0001599117 MNTR:FacilityOperationsRelatedMember 2020-01-01
2020-09-30 0001599117 MNTR:CorporateAndEliminationsMember
2020-01-01 2020-09-30 0001599117 MNTR:ConsolidatedMember 2020-01-01
2020-09-30 0001599117 MNTR:CannabisAndMedicalMarijuanaSegmentMember
2020-09-30 0001599117 MNTR:FacilityOperationsRelatedMember
2020-09-30 0001599117 MNTR:CorporateAndEliminationsMember
2020-09-30 0001599117 MNTR:ConsolidatedMember 2020-09-30 0001599117
us-gaap:SubsequentEventMember
MNTR:LegalRecoveryPurchaseAgreementMember 2021-10-04 2021-10-06
0001599117 us-gaap:SubsequentEventMember MNTR:PPPLoanMember
2021-10-25 2021-10-26 0001599117 us-gaap:SubsequentEventMember
MNTR:PPPLoanMember 2021-10-24 2021-10-26 iso4217:USD xbrli:shares
iso4217:USD xbrli:shares xbrli:pure
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
10-Q
☒ |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 |
For the
quarterly period ended
September 30,
2021
OR
☐ |
TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 |
For the
transition period from _______________ to
__________________
Commission
file number
000-55323
Mentor Capital, Inc. |
(Exact name
of registrant as specified in its charter) |
Delaware |
|
77-0395098 |
(State or
other jurisdiction of
incorporation or
organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
5964 Campus Court,
Plano,
Texas
75093 |
(Address of
principal executive offices) (Zip Code) |
Registrant’s
telephone number, including area code (760)
788-4700
Securities
registered pursuant to Section 12(b) of the Act:
N/A
|
|
|
|
|
Title of
each class to be so registered |
|
Trading
Symbols (s) |
|
Name of each
exchange on which each class is to be registered |
Securities
registered pursuant to section 12(g) of the Act:
Common
Stock |
(Title of
class) |
Indicate by
check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes ☒. No ☐.
Indicate by
check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Yes ☒. No ☐.
Indicate by
check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company, or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated filer,” “smaller reporting
company,” and “emerging growth company” in Rule 12b-2 of the
Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated filer |
☒ |
Smaller reporting
company |
☒ |
|
|
Emerging growth
company |
☒ |
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Indicate by
check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
At November
12, 2021, there were
22,850,947 shares of Mentor Capital, Inc.’s common stock
outstanding and 11 shares of Series Q Preferred Stock
outstanding.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report
contains “forward-looking statements,” as defined in the United
States Private Securities Litigation Reform Act of 1995 and Section
21E of the Securities and Exchange Act 1934, as amended. All
statements contained in this report, other than statements of
historical fact, including statements regarding our future results
of operations and financial position, our business strategy and
plans, and our objectives for future operations, are
forward-looking statements. The words “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “seek,” “look,” “hope,”
“intend,” “expect,” and similar expressions are intended to
identify forward-looking statements. We have based these
forward-looking statements largely on our current expectations and
projections about future events and trends that we believe may
affect our financial condition, results of operations, business
strategy, short-term and long-term business operations, and
objectives and financial needs. These forward-looking statements
are subject to a number of risks, uncertainties, and assumptions.
For example, statements in this Form 10-Q regarding the potential
future impact of COVID-19 on the Company’s business and results of
operations are forward-looking statements. Moreover, due to our
investments in the cannabis-related industry or other industries,
we may be subject to heightened scrutiny and our portfolio
companies may be subject to additional laws, rules, regulations,
and statutes. It is not possible for our management to predict all
risks, nor can we assess the impact of all factors on our business
or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in
any forward-looking statements we may make. In light of these
risks, uncertainties, and assumptions, the future events and trends
discussed in this Form 10-Q may not occur, and actual results could
differ materially and adversely from those anticipated or implied
in the forward-looking statements.
You should
not rely upon forward-looking statements as predictions of future
events. The events and circumstances reflected in the
forward-looking statements may not be achieved or occur. Although
we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance, or achievements. The Company
assumes no obligation to revise or update any forward-looking
statements for any reason, except as required by law.
All
references in this Form 10-Q to the “Company,” “Mentor,” “we,”
“us,” or “our” are to Mentor Capital, Inc.
MENTOR
CAPITAL, INC.
TABLE OF
CONTENTS
PART I.
FINANCIAL INFORMATION
Item 1. Financial
Statements
Mentor Capital, Inc.
Condensed
Consolidated Balance Sheets (Unaudited)
See
accompanying Notes to Financial Statements |
-4
- |
Mentor
Capital, Inc.
Condensed
Consolidated Balance Sheets (Unaudited, Continued)
|
|
September 30, |
|
|
December 31, |
|
|
|
2021 |
|
|
2020 |
|
|
|
|
|
|
|
|
LIABILITIES AND
SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
24,792 |
|
|
$ |
18,813 |
|
Accrued
expenses |
|
|
319,396 |
|
|
|
259,934 |
|
Related party
payable |
|
|
20,000 |
|
|
|
20,000 |
|
Deferred
revenue |
|
|
11,312 |
|
|
|
16,198 |
|
Paycheck
protection program loans, current portion |
|
|
- |
|
|
|
6,658 |
|
Finance lease
liability, current portion |
|
|
147,527 |
|
|
|
79,526 |
|
Operating lease
liability, current portion |
|
|
52,587 |
|
|
|
123,158 |
|
Current portion of long-term debt |
|
|
15,099 |
|
|
|
15,566 |
|
Total
current liabilities |
|
|
590,713 |
|
|
|
539,853 |
|
|
|
|
|
|
|
|
|
|
Long-term
liabilities |
|
|
|
|
|
|
|
|
Accrued salary,
retirement, and incentive fee - related party |
|
|
1,127,399 |
|
|
|
1,137,334 |
|
Related party
loan |
|
|
206,442 |
|
|
|
- |
|
Paycheck
protection program loans, net of current portion |
|
|
77,066 |
|
|
|
2,791 |
|
Economic injury
disaster loan |
|
|
156,862 |
|
|
|
152,602 |
|
Finance lease
liability, net of current portion |
|
|
373,892 |
|
|
|
190,976 |
|
Operating lease
liability, net of current portion |
|
|
12,377 |
|
|
|
16,150 |
|
Long
term debt, net of current portion |
|
|
50,717 |
|
|
|
66,246 |
|
Total
long-term liabilities |
|
|
2,004,755 |
|
|
|
1,566,099 |
|
Total liabilities |
|
|
2,595,468 |
|
|
|
2,105,952 |
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity |
|
|
|
|
|
|
|
|
Preferred stock, $0.0001
par value,
5,000,000 shares authorized;
11 and
11 shares issued and outstanding at September 30,
2021 and December 31, 2020 * |
|
|
- |
|
|
|
- |
|
Common stock, $0.0001
par value, 75,000,000
shares authorized; 22,850,947
and 22,850,947
shares issued and outstanding at September 30, 2021 and December
31, 2020 |
|
|
2,285 |
|
|
|
2,285 |
|
Additional paid in
capital |
|
|
13,071,655 |
|
|
|
13,071,655 |
|
Accumulated
deficit |
|
|
(10,968,166 |
) |
|
|
(10,601,231 |
) |
Non-controlling interest |
|
|
(152,609 |
) |
|
|
(137,566 |
) |
Total
shareholders’ equity |
|
|
1,953,165 |
|
|
|
2,335,143 |
|
Total liabilities and shareholders’ equity |
|
$ |
4,548,633 |
|
|
$ |
4,441,095 |
|
* |
Par value is less than
$0.01. |
See
accompanying Notes to Financial Statements |
-5
- |
Mentor Capital, Inc.
Condensed
Consolidated Income Statements (Unaudited)
* |
The company recorded an
operating loss; therefore the diluted EPS will not be calculated as
the diluted EPS effect is anti-dilutive. |
See
accompanying Notes to Financial Statements |
-6
- |
Mentor Capital, Inc.
Condensed
Consolidated Statement of Shareholders’ Equity
(Unaudited)
For the
Three Months Ended September 30, 2021 and 2020
* |
Par value of series Q
preferred shares is less than $1. |
See
accompanying Notes to Financial Statements |
-7
- |
Mentor Capital, Inc.
Condensed
Consolidated Statement of Shareholders’ Equity
(Unaudited)
For the Nine
Months Ended September 30, 2021 and 2020
|
Controlling
Interest |
|
|
|
Non- |
|
|
|
|
|
|
Preferred
stock |
|
|
Common stock |
|
|
Additional |
|
|
Accumulated |
|
|
|
|
|
|
controlling |
|
|
|
|
|
|
Shares |
|
|
$0.0001
par* |
|
|
Shares |
|
|
$0.0001
par |
|
|
paid in
capital |
|
|
equity
(deficit) |
|
|
|
Total |
|
|
|
equity
(deficit) |
|
|
Totals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2020 |
|
|
11 |
|
|
$ |
- |
|
|
|
22,850,947 |
|
|
$ |
2,285 |
|
|
$ |
13,071,655 |
|
|
$ |
(10,601,231 |
) |
|
$ |
2,472,709 |
|
|
$ |
(137,566 |
) |
|
$ |
2,335,143 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(366,935 |
) |
|
|
(366,935 |
) |
|
|
(15,043 |
) |
|
|
(381,978 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2021 |
|
|
11 |
|
|
$ |
- |
|
|
|
22,850,947 |
|
|
$ |
2,285 |
|
|
$ |
13,071,655 |
|
|
$ |
(10,968,166 |
) |
|
$ |
2,105,774 |
|
|
$ |
(152,609 |
) |
|
$ |
1,953,165 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2019 |
|
|
11 |
|
|
$ |
- |
|
|
|
22,850,947 |
|
|
$ |
2,285 |
|
|
$ |
13,071,655 |
|
|
$ |
(9,875,206 |
) |
|
$ |
3,198,734 |
|
|
$ |
(186,050 |
) |
|
$ |
3,012,684 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(705,910 |
) |
|
|
(705,910 |
) |
|
|
(92,463 |
) |
|
|
(798,373 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at September 30, 2020 |
|
|
11 |
|
|
$ |
- |
|
|
|
22,850,947 |
|
|
$ |
2,285 |
|
|
$ |
13,071,655 |
|
|
$ |
(10,581,116 |
) |
|
$ |
2,492,824 |
|
|
$ |
(278,513 |
) |
|
$ |
2,214,311 |
|
Balance September 30, 2020 |
|
|
11 |
|
|
$ |
- |
|
|
|
22,850,947 |
|
|
$ |
2,285 |
|
|
$ |
13,071,655 |
|
|
$ |
(10,581,116 |
) |
|
$ |
2,492,824 |
|
|
$ |
(278,513 |
) |
|
$ |
2,214,311 |
|
* |
Par value of series Q
preferred shares is less than $1. |
See
accompanying Notes to Financial Statements |
-8
- |
Mentor Capital, Inc.
Condensed
Consolidated Statements of Cash Flows (Unaudited)
See
accompanying Notes to Financial Statements |
-9
- |
Mentor
Capital, Inc.
Condensed
Consolidated Statements of Cash Flows (Unaudited,
Continued)
|
|
For the Nine Months
Ended |
|
|
|
Ended
September 30, |
|
|
|
2021 |
|
|
2020 |
|
CASH FLOWS FROM
FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
Proceeds from related party loan |
|
$ |
204,006 |
|
|
$ |
- |
|
Proceeds from
Paycheck Protection Program loan |
|
|
76,593 |
|
|
|
459,842 |
|
Proceeds from
economic injury disaster loan |
|
|
- |
|
|
|
150,000 |
|
Refund of Paycheck
Protection Program payments |
|
|
551 |
|
|
|
- |
|
Payments on
related party payable |
|
|
- |
|
|
|
(27,472 |
) |
Payments on
long-term debt |
|
|
(15,996 |
) |
|
|
(19,518 |
) |
Payments on finance lease liability |
|
|
(90,082 |
) |
|
|
(40,383 |
) |
|
|
|
|
|
|
|
|
|
Net
cash provided by (used by) financing activities |
|
|
175,072 |
|
|
|
522,469 |
|
|
|
|
|
|
|
|
|
|
Net change in cash |
|
|
(228,106 |
) |
|
|
(35,653 |
) |
|
|
|
|
|
|
|
|
|
Beginning
cash |
|
|
506,174 |
|
|
|
686,611 |
|
|
|
|
|
|
|
|
|
|
Ending cash |
|
$ |
278,068 |
|
|
$ |
650,958 |
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTARY
INFORMATION: |
|
|
|
|
|
|
|
|
Cash
paid for interest |
|
$ |
43,899 |
|
|
$ |
22,697 |
|
|
|
|
|
|
|
|
|
|
Cash
paid for income taxes |
|
$ |
8,565 |
|
|
$ |
9,170 |
|
|
|
|
|
|
|
|
|
|
NON-CASH INVESTING
AND FINANCING TRANSACTIONS: |
|
|
|
|
|
|
|
|
Right
of use assets acquired through operating lease liability |
|
$ |
55,624 |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
Right
of use assets acquired through finance lease liability |
|
$ |
340,999 |
|
|
$ |
143,909 |
|
See
accompanying Notes to Financial Statements |
-10
- |
Note 1 - Nature of
operations
Corporate Structure
Overview
Mentor
Capital, Inc. (“Mentor” or “the Company”), reincorporated under the
laws of the State of Delaware
in September 2015.
The entity
was originally founded as an investment partnership in Silicon
Valley, California, by the current CEO in 1985 and subsequently
incorporated under the laws of the State of California on July 29,
1994. On September 12, 1996, the Company’s offering
statement was qualified pursuant to Regulation A of the Securities
Act, and the Company began to trade its shares publicly. On August
21, 1998, the Company filed for voluntary reorganization, and on
January 11, 2000, the Company emerged from Chapter 11
reorganization. The Company relocated to San Diego, California, and
contracted to provide financial assistance and investment into
small businesses. On May 22, 2015, a corporation named Mentor
Capital, Inc. (“Mentor Delaware”) was incorporated under the laws
of the State of Delaware. A shareholder-approved merger between
Mentor and Mentor Delaware was approved by the California and
Delaware Secretaries of State and became effective September 24,
2015, thereby establishing Mentor as a Delaware corporation. In
September 2020, Mentor relocated its corporate office from San
Diego, California, to Plano, Texas.
The
Company’s common stock trades publicly under the trading symbol
OTCQB: MNTR.
The
Company’s broad target industry focus includes energy, mining and
minerals, technology, consumer products, management services, and
manufacturing sectors with the goal of ensuring increased market
opportunities and investment diversification. In April 2021, the
Company announced that it was adding a cryptocurrency focus for
Mentor.
Mentor has a
51% interest in Waste
Consolidators, Inc. (“WCI”). WCI was incorporated in Colorado in
1999 and operates in Arizona and Texas. It is a long standing
investment of the Company since 2003.
On April 18,
2016, the Company formed Mentor IP, LLC (“MCIP”), a South Dakota
limited liability company and wholly owned subsidiary of Mentor.
MCIP was formed to hold interests related to patent rights obtained
on April 4, 2016, when Mentor Capital, Inc. entered into that
certain “Larson - Mentor Capital, Inc. Patent and License Fee
Facility with Agreement Provisions for an — 80% /
20% Domestic Economic Interest —
50% /
50% Foreign Economic Interest” with R. L. Larson and Larson
Capital, LLC (“MCIP Agreement”). Pursuant to the MCIP Agreement,
MCIP obtained rights to an international patent application for
foreign THC and CBD cannabis vape pens under the provisions of the
Patent Cooperation Treaty of 1970, as amended. R. L. Larson
continues its efforts to obtain exclusive licensing rights in the
United States for THC and CBD cannabis vape pens for various THC
and CBD percentage ranges and concentrations. On May 5, 2020, a
patent was issued by the United States Patent and Trademark Office
and on September 22, 2020, a patent was issued by the Canadian
Intellectual Property Office. Patent application national phase
maintenance fees were expensed when paid rather than capitalized
and therefore, no capitalized assets related to MCIP are recognized
on the consolidated financial statements at September 30, 2021 and
December 31, 2020.
Mentor
Partner I, LLC (“Partner I”) was reorganized as a limited liability
company under the laws of the State of Texas as of February 17,
2021. The entity was initially organized as a limited liability
company under the laws of the State of California on September 19,
2017. Partner I was formed as a wholly owned subsidiary of Mentor
for the purpose of cannabis-focused acquisition and investment. In
2018, Mentor contributed $996,000
of capital to Partner I to facilitate the purchase of manufacturing
equipment to be leased from Partner I by G FarmaLabs Limited (“G
Farma”) under a Master Equipment Lease Agreement dated January 16,
2018, as amended. Amendments expanded the Lessee under the
agreement to include G FarmaLabs Limited and G FarmaLabs DHS, LLC,
(collectively referred to as “G Farma Lease Entities”). The finance
leases resulting from this investment were fully impaired at
September 30, 2021 and December 31, 2020. See Note 8.
Mentor
Partner II, LLC (“Partner II”) was reorganized as a limited
liability company under the laws of the State of Texas on February
17, 2021. The entity was initially organized as a limited liability
company under the laws of the State of California on February 1,
2018. Partner II was formed as a wholly owned subsidiary of Mentor
for the purpose of cannabis-focused investing and acquisition. On
February 8, 2018, Mentor contributed $400,000
to Partner
II to facilitate the purchase of manufacturing equipment to be
leased from Partner II by Pueblo West Organics, LLC, a Colorado
limited liability company (“Pueblo West”) under a Master Equipment
Lease Agreement dated February 11, 2018, as amended. On March 12,
2019, Mentor agreed to use Partner II earnings of $61,368
to
facilitate the purchase of additional manufacturing equipment to
Pueblo West under a Second Amendment to the lease. This lease is
fully performing, see Note 8.
Note 1 -
Nature of operations (continued)
The Company
has a membership equity interest in Electrum Partners, LLC
(“Electrum”) which is carried at a cost of $194,028 and $194,028
at September 30, 2021 and December 31, 2020,
respectively.
On October
30, 2018, the Company entered into a Recovery Purchase Agreement
with Electrum. Electrum is the plaintiff in an ongoing legal action
pending in the Supreme Court of British Columbia (“Litigation”). As
described further in Note 9, Mentor provided capital for payment of
Litigation costs in the amount of $181,529
and
$146,195
as of
December 31, 2020 and 2019, respectively. After repayment to Mentor
of all funds invested for payment of Litigation costs, Mentor will
receive 18% of anything of value received by Electrum as a result
of the Litigation (“Recovery”), after first receiving reimbursement
of the Litigation costs. On October 31, 2018, Mentor entered into a
secured Capital Agreement with Electrum and invested an additional
$100,000
of capital
in Electrum.
Under the Capital Agreement, on the payment date, Electrum will pay
Mentor the sum of (i) $100,000, (ii) ten percent (10%) of the
Recovery, and (iii) 0.083334% of the Recovery for each full month
from October 31, 2018 to the payment date for each full month that
$833 is not paid to Mentor. The payment date is the earlier of
November 1, 2021, or the final resolution of the
Litigation. On January 28, 2019, the
Company entered into a second secured Capital Agreement with
Electrum and invested an additional $100,000
of capital
in Electrum with payment terms similar to the October 31, 2018
Capital Agreement. As part of the January 28, 2019 Capital
Agreement, Mentor was granted an option to convert its 6,198
membership interests in Electrum into a cash payment of $194,028
plus an
additional 19.4% of the Recovery. See
Note 9. Subsequent to quarter end, on October 6, 2021, the Company
invested additional capital of $9,998
for
Litigation costs which increased the percentage of what Mentor will
receive to 19%
of the Recovery, after first receiving reimbursement of Litigation
costs, see Note 20.
On December
21, 2018, Mentor paid $10,000 to purchase 500,000 shares of NeuCourt,
Inc. common stock, representing approximately 6.1% of
NeuCourt’s issued and outstanding common stock as of September 30,
2021.
Note 2 -
Summary of significant
accounting policies
Condensed consolidated
financial statements
The
unaudited condensed consolidated financial statements of the
Company for the nine month period ended September 30, 2021 and 2020
have been prepared in accordance with accounting principles
generally accepted in the United States of America for interim
financial information and pursuant to the requirements for
reporting on Form 10-Q and Regulation S-K. Accordingly, they do not
include all the information and footnotes required by accounting
principles generally accepted in the United States of America for
complete financial statements. However, such information reflects
all adjustments (consisting solely of normal recurring
adjustments), which are, in the opinion of management, necessary
for the fair presentation of the financial position and the results
of operations. Results shown for interim periods are not
necessarily indicative of the results to be obtained for a full
fiscal year. The balance sheet information as of December 31, 2020
was derived from the audited financial statements included in the
Company’s financial statements as of and for the year ended
December 31, 2020 included in the Company’s Annual Report on Form
10-K filed with the Securities and Exchange Commission (the “SEC”)
on April 15, 2021. These financial statements should be read in
conjunction with that report.
Basis of
presentation
The
accompanying consolidated financial statements and related notes
include the activity of subsidiaries in which a controlling
financial interest is owned. The consolidated financial statements
have been prepared in accordance with accounting principles
generally accepted in the United States of America (“GAAP”).
Significant intercompany balances and transactions have been
eliminated in consolidation. Certain prior period amounts have been
reclassified to conform with the current period
presentation.
Basis of presentation
(continued)
As shown in
the accompanying financial statements, the Company has a
significant accumulated deficit of $10,968,166 as of September 30,
2021. The Company continues to experience negative cash flows from
operations.
The Company
management believes it is more likely than not that Electrum will
prevail in the legal action described in Note 9 to the consolidated
financial statements, in which the Company has an interest.
However, there is no surety that Electrum will prevail in its legal
action or that we will be able to recover our funds and our
percentage of the Litigation Recovery if Electrum does
prevail.
Note 2 -
Summary of significant accounting policies
(continued)
Going Concern
Uncertainties
The Company
will be required to raise additional capital to fund its operations
and will continue to attempt to raise capital resources from both
related and unrelated parties until such time as the Company is
able to generate revenues sufficient to maintain itself as a viable
entity. These factors have raised substantial doubt about the
Company’s ability to continue as a going concern. These financial
statements are presented on the basis that we will continue as a
going concern. The going concern concept contemplates the
realization of assets and satisfaction of liabilities in the normal
course of business. The financial statements do not include any
adjustments that might be necessary if the Company is unable to
continue as a going concern. There can be no assurances that the
Company will be able to raise additional capital or achieve
profitability. However, the Company has 6,252,954 Series D warrants
outstanding in which the Company can reset the exercise price
substantially below the current market price. These condensed
consolidated financial statements do not include any adjustments
that might result from repricing the outstanding
warrants.
Management’s
plans include increasing revenues through acquisition, investment,
and organic growth. Management anticipates funding these activities
by raising additional capital through the sale of equity securities
and debt.
Impact Related to
COVID-19
The effect
of the novel coronavirus (“COVID-19”) has significantly impacted
the United States and the global economy. COVID-19 and the measures
taken by many countries in response have adversely affected and
could in the future materially adversely impact the Company’s
business, results of operations, financial condition, and stock
price. As of September 30, 2021, the fatality rate from COVID-19 in
the United States has significantly declined from its peak, but the
impact of COVID-19 continues to unfold. The ongoing worldwide
economic situation, future weakness in the credit markets, and
significant liquidity problems for the financial services industry
may impact our financial condition in a number of ways. For
example, our current or potential customers, or the current or
potential customers of our partners or affiliates, may delay or
decrease spending with us, or may not pay us, or may delay paying
us for previously purchased products and services. Also, we, or our
partners or affiliates, may have difficulties in securing
additional financing. Our legal recovery efforts have been hindered
and may continue to be constrained due to the closure of the courts
in California and British Columbia, which may cause
COVID-19-related scheduling delays, hindering our legal recovery
from the G Farma Entities and delaying the receipt of the Company’s
interest in the Electrum Partners, LLC legal recovery,
respectively. Additionally, the collectability of our investment in
accounts receivable has been impaired by $139,148 in the fourth
quarter of 2020, due to a reduction in our expected collection
amount of the 2020 and 2021 payments of an installment contract,
see Note 4.
Public
health efforts to mitigate the impact of COVID-19 have included
government actions such as travel restrictions, limitations on
public gatherings, shelter in place orders, and mandatory closures.
These actions are being lifted to varying degrees. WCI has not
experienced an overall reduced demand for services initially
anticipated because WCI helps lower monthly service costs paid by
its client properties. However, WCI’s clients may experience a
delay in collecting rent from tenants, which may cause slower
payments to WCI. WCI closely monitors customer accounts and has not
experienced significant delays in the collection of accounts
receivable.
According to
the Critical Infrastructure Standards released by the Cybersecurity
and Infrastructure Security Agency on March 18, 2020, “Financial
Services Sector” businesses, like Mentor, are considered “essential
businesses.” Because of the financial nature of Mentor’s
operations, which consist of oversight of our portfolio companies,
accounting, compliance, investor relations, and sales, Mentor’s
day-to-day operations are not substantially hindered by remote
office work or telework.
We
anticipate that current cash and associated resources will be
sufficient to execute our business plan for the next twelve months.
The ultimate impact of COVID-19 on our business, results of
operations, financial condition and cash flows is dependent on
future developments, including the duration of COVID-19, government
response and the related length of this impact on the economy,
which are uncertain and cannot be predicted at this
time.
Use of
estimates
The
preparation of our condensed consolidated financial statements in
conformity with GAAP requires management to make estimates,
assumptions, and judgments that affect the reported amounts of
assets and liabilities, and the disclosure of contingent assets and
liabilities at the date of our consolidated financial statements,
and the reported amount of revenues and expenses during the
reporting period.
Note 2 -
Summary of significant accounting policies
(continued)
Significant
estimates relied upon in preparing these consolidated financial
statements include revenue recognition, accounts and notes
receivable reserves, expected future cash flows used to evaluate
the recoverability of long-lived assets, estimated fair values of
long-lived assets used to record impairment charges related to
investments, goodwill, amortization periods, accrued expenses, and
recoverability of the Company’s net deferred tax assets and any
related valuation allowance.
Although the
Company regularly assesses these estimates, actual results could
differ materially from these estimates. Changes in estimates are
recorded in the period in which they become known. The Company
bases its estimates on historical experience and various other
assumptions that it believes to be reasonable under the
circumstances. Actual results may differ from management’s
estimates if past experience or other assumptions do not turn out
to be substantially accurate.
Recent Accounting
Standards
From time to
time, the FASB or other standards setting bodies issue new
accounting pronouncements. Updates to the FASB Accounting Standard
Codifications (“ASCs”) are communicated through the issuance of an
Accounting Standards Update (“ASU”). Unless otherwise discussed, we
believe that the impact of recently issued guidance, whether
adopted or to be adopted in the future, is not expected to have a
material impact on our consolidated financial statements upon
adoption.
There were
no accounting pronouncements issued during the nine months ended
September 30, 2021 that are expected to have a material impact on
the Company’s condensed consolidated financial
statements.
Concentrations of
cash
The Company
maintains its cash and cash equivalents in bank deposit accounts,
which at times may exceed federally insured limits. The Company has
not experienced any losses in such accounts, nor does the Company
believe it is exposed to any significant credit risk on cash and
cash equivalents.
Cash and cash
equivalents
The Company
considers all short-term debt securities purchased with a maturity
of three months or less to be cash equivalents. The Company had no
short-term debt securities as of September 30, 2021 and December
31, 2020.
Accounts
receivable
Accounts
receivable consists of trade accounts arising in the normal course
of business and are classified as current assets and carried at
original invoice amounts less an estimate for doubtful receivables
based on historical losses as a percent of revenue in conjunction
with a review of outstanding balances on a quarterly basis. The
estimate of the allowance for doubtful accounts is based on the
Company’s bad debt experience, market conditions, and aging of
accounts receivable, among other factors. If the financial
condition of the Company’s customers deteriorates, resulting in the
customer’s inability to pay the Company’s receivables as they come
due, additional allowances for doubtful accounts will be required.
At September 30, 2021 and December 31, 2020, the Company has an
allowance for doubtful receivables in the amount of $79,041 and
$59,461,
respectively.
Investments in securities at
fair value
Investment
in securities consists of debt and equity securities reported at
fair value. Under ASU 2016-01, “Financial Instruments - Overall:
Recognition and Measurement of Financial Assets and Financial
Liabilities,” the Company elected to report changes in the fair
value of equity investment in realized investment gains (losses),
net.
Long term
investments
The
Company’s investments in entities where it is a minority owner and
does not have the ability to exercise significant influence are
recorded at fair value if readily determinable. If the fair market
value is not readily determinable, the investment is recorded under
the cost method. Under this method, the Company’s share of the
earnings or losses of such investee company is not included in the
Company’s financial statements. The Company reviews the carrying
value of its long-term investments for impairment each reporting
period.
Note 2 -
Summary of significant accounting policies
(continued)
Investments in debt
securities
The
Company’s investment in debt securities consists of two convertible
notes receivable from NeuCourt, Inc., which are recorded at the
aggregate principal face amount of $75,000
plus accrued interest of $10,087
and $7,038
at September 30, 2021 and December 31, 2020, respectively, as
presented in Note 7.
Investment in account
receivable, net of discount
The
Company’s investment in account receivable is stated at face value,
net of unamortized purchase discount. The discount is amortized to
interest income over the term of the exchange agreement. In the
fourth quarter of 2020, we were notified that due to the effect of
COVID-19 on the estimated receivable, we may not receive the 2020
installment payment or the full 2021 installment payment. At
September 30, 2021 and December 31, 2020, the Company has an
impairment of the investment in account receivable of $139,148
and $139,148,
respectively.
Credit quality of notes
receivable and finance leases receivable, and credit loss
reserve
As our notes
receivable and finance leases receivable are limited in number, our
management is able to analyze estimated credit loss reserves based
on a detailed analysis of each receivable as opposed to using
portfolio-based metrics. Our management does not use a system of
assigning internal risk ratings to each of our receivables. Rather,
each note receivable and finance lease receivable is analyzed
quarterly and categorized as either performing or non-performing
based on certain factors including, but not limited to, financial
results, satisfying scheduled payments, and compliance with
financial covenants. A note receivable or finance lease receivable
will be categorized as non-performing when a borrower experiences
financial difficulty and has failed to make scheduled payments. As
part of the monitoring process, we may physically inspect the
collateral or a borrower’s facility and meet with a borrower’s
management to better understand such borrower’s financial
performance and its future plans on an as-needed basis.
Lessee
Leases
We determine
whether an arrangement is a lease at inception. Lessee leases are
classified as either finance leases or operating leases. A lease is
classified as a finance lease if any one of the following criteria
is met: (i) the lease transfers ownership of the asset by the end
of the lease term, (ii) the lease contains an option to purchase
the asset that is reasonably certain to be exercised, and (iii) the
lease term is for a significant part of the remaining useful life
of the asset or the present value of the lease payments equals or
exceeds substantially all of the fair value of the asset. A lease
is classified as an operating lease if it does not meet any one of
these criteria. Our operating leases are comprised of office space
leases and office equipment. Fleet vehicle leases entered into
prior to January 1, 2019, are classified as operating leases based
on an expected lease term of four years. Fleet vehicle leases
entered into on or after January 1, 2019, for which the lease is
expected to be extended to five years, are classified as finance
leases. Our leases have remaining lease terms of one to forty-eight
months. Our fleet finance leases contain a residual value guarantee
which, based on past lease experience, is unlikely to result in a
liability at the end of the lease. As most of our leases do not
provide an implicit rate, we use our incremental borrowing rate
based on the information available at the commencement date in
determining the present value of lease payments.
Costs
associated with operating lease assets are recognized on a
straight-line basis, over the term of the lease, within cost of
goods sold for vehicles used in direct servicing of WCI customers
and in operating expenses for costs associated with all other
operating leases. Finance lease assets are amortized within cost of
goods sold for vehicles used in direct servicing of WCI customers
and within operating expenses for all other finance lease assets,
on a straight-line basis over the shorter of the estimated useful
lives of the assets or the lease term. The interest component of a
finance lease is included in interest expense and recognized using
the effective interest method over the lease term. We have
agreements that contain both lease and non-lease components. For
vehicle fleet operating leases, we account for lease components
together with non-lease components (e.g., maintenance
fees).
Note 2 -
Summary of significant accounting policies
(continued)
Property, and
equipment
Property and
equipment is recorded at cost less accumulated depreciation.
Depreciation is computed on the declining balance method over the
estimated useful lives of various classes of property. The
estimated lives of the property and equipment are generally as
follows: computer equipment, three to five years; furniture and
equipment, seven years; and vehicles and trailers, four to five
years. Depreciation on vehicles used by WCI to service its
customers is included in cost of goods sold in the consolidated
income statements. All other depreciation is included in selling,
general and administrative costs in the consolidated income
statements.
Expenditures
for major renewals and improvements are capitalized, while minor
replacements, maintenance and repairs, which do not extend the
asset lives, are charged to operations as incurred. Upon sale or
disposition, the cost and related accumulated depreciation are
removed from the accounts and any gain or loss is included in
operations. The Company continually monitors events and changes in
circumstances that could indicate that the carrying balances of its
property and equipment may not be recoverable in accordance with
the provisions of ASC 360, “Property, Plant, and Equipment.”
When such events or changes in circumstances are present, the
Company assesses the recoverability of long-lived assets by
determining whether the carrying value of such assets will be
recovered through undiscounted expected future cash flows. If the
total of the future cash flows is less than the carrying amount of
those assets, the Company recognizes an impairment loss based on
the excess of the carrying amount over the fair value of the
assets.
The Company
reviews intangible assets subject to amortization quarterly to
determine if any adverse conditions exist or a change in
circumstances has occurred that would indicate impairment or a
change in the remaining useful life. Conditions that may indicate
impairment include, but are not limited to, a significant adverse
change in legal factors or business climate that could affect the
value of an asset, a product recall, or an adverse action or
assessment by a regulator. If an impairment indicator exists, we
test the intangible asset for recoverability. For purposes of the
recoverability test, we group our amortizable intangible assets
with other assets and liabilities at the lowest level of
identifiable cash flows if the intangible asset does not generate
cash flows independent of other assets and liabilities. If the
carrying value of the intangible asset (asset group) exceeds the
undiscounted cash flows expected to result from the use and
eventual disposition of the intangible asset (asset group), the
Company will write the carrying value down to the fair value in the
period identified.
Goodwill
Goodwill of
$1,324,142 was derived from
consolidating WCI effective January 1, 2014, and $102,040
of goodwill related to the 1999 acquisition of a 50% interest in WCI.
In accordance with ASC 350, “Intangibles-Goodwill and
Other,” goodwill and other intangible assets with indefinite
lives are no longer subject to amortization but are tested for
impairment annually or whenever events or changes in circumstances
indicate that the asset might be impaired.
The Company
reviews the goodwill allocated to each of our reporting units for
possible impairment annually as of December 31 and whenever events
or changes in circumstances indicate carrying amount may not be
recoverable. In the impairment test, the Company measures the
recoverability of goodwill by comparing a reporting unit’s carrying
amount, including goodwill, to the estimated fair value of the
reporting unit. If the carrying amount of a reporting unit is in
excess of its fair value, the Company recognizes an impairment
charge equal to the amount in excess. To estimate the fair value,
management uses valuation techniques which included the discounted
value of estimated future cash flows. The evaluation of impairment
requires the Company to make assumptions about future cash flows
over the life of the asset being evaluated. These assumptions
require significant judgment and are subject to change as future
events and circumstances change. Actual results may differ from
assumed and estimated amounts. Management determined that no
impairment write-downs were required as of September 30, 2021 and
December 31, 2020.
Note 2 -
Summary of significant accounting policies
(continued)
Revenue
recognition
The Company
recognizes revenue in accordance with ASC 606, “Revenue from
Contracts with Customers,” and FASB ASC Topic 842,
“Leases.” Revenue is recognized net of allowances for
returns and any taxes collected from customers, which are
subsequently remitted to government authorities.
WCI works
with business park owners, governmental centers, and apartment
complexes to reduce facilities related costs. WCI performs monthly
services pursuant to agreements with customers. Customer monthly
service fees are based on WCI’s assessment of the amount and
frequency of monthly services requested by a customer. WCI may also
provide additional services, such as apartment cleanout services,
large item removals, or similar services, on an as needed basis at
an agreed upon rate as requested by customers. All services are
invoiced and recognized as revenue in the month the agreed on
services are performed.
For each
finance lease, the Company recognized as a gain the amount equal to
(i) the net investment in the finance lease less (ii) the net book
value of the equipment at the inception of the applicable lease. At
lease inception, we capitalize the total minimum finance lease
payments receivable from the lessee, the estimated unguaranteed
residual value of the equipment at lease termination, if any, and
the initial direct costs related to the lease, less unearned
income. Unearned income is recognized as finance income over the
term of the lease using the effective interest rate
method.
The Company,
through its subsidiaries, is the lessor of manufacturing equipment
subject to leases under master leasing agreements. The leases
contain an element of dealer profit and lessee bargain purchase
options at prices substantially below the subject assets’ estimated
residual values at the exercise date for the options. Consequently,
the Company classified the leases as sales-type leases (the
“finance leases”) for financial accounting purposes. For such
finance leases, the Company reports the discounted present value of
(i) future minimum lease payments (including the bargain purchase
option, if any) and (ii) any residual value not subject to a
bargain purchase option as a finance lease receivable on its
balance sheet and accrues interest on the balance of the finance
lease receivable based on the interest rate inherent in the
applicable lease over the term of the lease. For each finance
lease, the Company recognized revenue in an amount equal to the net
investment in the lease and cost of sales equal to the net book
value of the equipment at the inception of the applicable
lease.
Basic and diluted income (loss)
per common share
We compute
net income (loss) per share in accordance with ASC 260,
“Earnings Per Share.” Under the provisions of ASC 260, basic
net loss per share includes no dilution and is computed by dividing
the net loss available to common stockholders for the period by the
weighted average number of shares of Common Stock outstanding
during the period. Diluted net income (loss) per share takes into
consideration shares of Common Stock outstanding (computed under
basic net loss per share) and potentially dilutive securities that
are not anti-dilutive.
Outstanding
warrants that had no effect on the computation of the dilutive
weighted average number of shares outstanding as their effect would
be anti-dilutive were approximately
7,000,000 and
7,000,000 as of September 30, 2021 and December 31, 2020,
respectively. There were 87,456 and
87,456
potentially dilutive shares outstanding at September 30, 2021 and
December 31, 2020, respectively.
Conversion
of Series Q Preferred Stock into Common Stock would be
anti-dilutive for the three and nine months ended September 30,
2021 and 2020 and is not included in calculating the diluted
weighted average number of shares outstanding.
Note 3 –
Prepaid expenses and
other assets
Prepaid
expenses and other assets consist of the following:
Schedule
of prepaid expenses and other assets
|
|
September 30, 2021 |
|
|
December 31, 2020 |
|
Prepaid insurance |
|
|
- |
|
|
|
342 |
|
Other prepaid
costs |
|
|
25,444 |
|
|
|
17,497 |
|
Prepaid
expenses and other current assets |
|
$ |
25,444 |
|
|
$ |
17,839 |
|
Note 4
– Investment in
account receivable
On April 10,
2015, the Company entered into an exchange agreement whereby the
Company received an investment in an account receivable with annual
installment payments of $117,000 for 11 years,
through 2026, totaling $1,287,000 in
exchange for 757,059
shares of Mentor Common Stock obtained through exercise of
Series D warrants at
$1.60 per share plus a
$0.10 per warrant redemption
price.
The Company
valued the transaction based on the market value of Company common
shares exchanged in the transaction, resulting in a 17.87%
discount from the face value of the account receivable. The
discount is being amortized monthly to interest over the 11-year
term of the agreement. In the fourth quarter of 2020, we were
notified that due to the effect of COVID-19 on the estimated
receivable, we may not receive the 2020 installment payment or the
full 2021 installment payment. Based on management’s collection
estimates, we have recorded an impairment of $139,148
and
$139,148
on the
investment in account receivable at September 30, 2021 and December
31, 2020, respectively.
The
investment in account receivable consists of the following at
September 30, 2021 and December 31, 2020:
Schedule
of receivables with imputed interest
|
|
September 30,
2021 |
|
|
December 31,
2020 |
|
Face value |
|
$ |
702,000 |
|
|
$ |
702,000 |
|
Impairment |
|
|
(139,148 |
) |
|
|
(139,148 |
) |
Unamortized
discount |
|
|
(187,110 |
) |
|
|
(232,794 |
) |
Net balance |
|
|
375,742 |
|
|
|
330,058 |
|
Current portion |
|
|
117,000 |
|
|
|
(26,162 |
) |
Long
term portion |
|
$ |
258,742 |
|
|
$ |
303,896 |
|
For the
three months ended September 30, 2021 and 2020, $15,228
and $23,691
of discount amortization is included in interest income,
respectively. For the nine months ended September 30, 2021 and
2020, $45,684
and $61,908
of discount amortization is included in interest income,
respectively.
Note 5 -
Property and
equipment
Property and
equipment are comprised of the following:
Schedule of property, plant and
equipment
|
|
September 30,
2021 |
|
|
December 31,
2020 |
|
Computers |
|
$ |
39,809 |
|
|
$ |
38,545 |
|
Furniture and fixtures |
|
|
23,428 |
|
|
|
23,428 |
|
Machinery and
vehicles |
|
|
205,625 |
|
|
|
205,187 |
|
Property
and equipment |
|
|
268,862 |
|
|
|
267,160 |
|
Accumulated
depreciation and amortization |
|
|
(147,404 |
) |
|
|
(129,974 |
) |
|
|
|
|
|
|
|
|
|
Net Property
and equipment |
|
$ |
121,458 |
|
|
$ |
137,186 |
|
Depreciation
and amortization expense was $15,031
and
$5,585
for the
three months ended September 30, 2021 and 2020, respectively.
Depreciation and amortization expense was $34,305
and
$14,869
for the nine
months ended September 30, 2021 and 2020, respectively.
Depreciation on WCI vehicles used to service customer accounts is
included in the cost of goods sold, and all other depreciation is
included in selling, general and administrative expenses in the
condensed consolidated income statements.
Note 6 –
Lessee
Leases
Operating
leases are comprised of office space and office equipment leases.
Fleet leases entered into prior to January 1, 2019, are classified
as operating leases. Fleet leases entered into on or after January
1, 2019, under ASC 842 guidelines, are classified as finance
leases.
Gross right
of use assets recorded under finance leases related to WCI vehicle
fleet leases were $777,451 and
$406,242 as
of September 30, 2021 and December 31, 2020, respectively.
Accumulated amortization associated with finance leases was
$202,861
and $110,164
as of September 30, 2021 and December 31, 2020,
respectively.
Lease costs
recognized in our consolidated statements of operations is
summarized as follows:
Schedule of lease costs
recognized in consolidated statements of
operations
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Operating lease cost
included in cost of goods |
|
$ |
27,868 |
|
|
$ |
35,581 |
|
|
$ |
90,569 |
|
|
$ |
120,153 |
|
Operating lease
cost included in operating costs |
|
|
13,496 |
|
|
|
13,846 |
|
|
|
35,788 |
|
|
|
41,965 |
|
Total
operating lease cost (1) |
|
|
41,364 |
|
|
|
49,427 |
|
|
|
126,357 |
|
|
|
162,118 |
|
Finance lease cost, included in cost
of goods: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of
lease assets |
|
|
41,111 |
|
|
|
19,349 |
|
|
|
90,082 |
|
|
|
50,776 |
|
Interest on lease liabilities |
|
|
6,765 |
|
|
|
4,719 |
|
|
|
18,595 |
|
|
|
12,689 |
|
Total
finance lease cost |
|
|
47,876 |
|
|
|
24,068 |
|
|
|
108,677 |
|
|
|
63,465 |
|
Short-term
lease cost |
|
|
0 |
|
|
|
5,980 |
|
|
|
2,300 |
|
|
|
23,920 |
|
Total
lease cost |
|
$ |
89,240 |
|
|
$ |
79,475 |
|
|
$ |
237,334 |
|
|
$ |
249,503 |
|
|
(1) |
Right of use asset
amortization under operating agreements was $39,006
and $45,707
for the three months ended September 30, 2021 and 2020,
respectively. Right of use asset amortization under operating
agreements was $106,545
and $141,429
for the nine months ended September 30, 2021 and 2020,
respectively. |
Other
information about lease amounts recognized in our condensed
consolidated financial statements is summarized as
follows:
Schedule of other information
about lease amounts recognized in Condensed Consolidated Financial
Statements
|
|
September 30,
2021
|
|
|
December 31,
2020
|
|
Weighted-average
remaining lease term – operating leases |
|
|
0.7 |
|
|
|
0.93
years |
|
Weighted-average remaining lease
term – finance leases |
|
|
3.83 |
|
|
|
3.41
years |
|
Weighted-average discount rate –
operating leases |
|
|
2.9 |
% |
|
|
10.1 |
% |
Weighted-average discount rate –
finance leases |
|
|
4.6 |
% |
|
|
8.3 |
% |
Finance
lease liabilities were as follows:
Schedule of Finance lease
liabilities
|
|
September 30,
2021
|
|
|
December 31,
2020
|
|
Gross finance lease
liabilities |
|
$ |
566,867 |
|
|
$ |
310,685 |
|
Less:
imputed interest |
|
|
(45,448 |
) |
|
|
(40,183 |
) |
Present value of finance lease
liabilities |
|
|
521,419 |
|
|
|
270,502 |
|
Less:
current portion |
|
|
(147,527 |
) |
|
|
(79,526 |
) |
Long-term
finance lease liabilities |
|
$ |
373,892 |
|
|
$ |
190,976 |
|
Operating
lease liabilities were as follows:
Schedule of operating lease
liabilities
|
|
September 30,
2021
|
|
|
December 31,
2020
|
|
Gross operating lease
liabilities |
|
$ |
67,147 |
|
|
$ |
146,171 |
|
Less:
imputed interest |
|
|
(2,183 |
) |
|
|
(6,863 |
) |
Present value
of operating lease liabilities |
|
|
64,964 |
|
|
|
139,308 |
|
Less:
current portion |
|
|
(52,587 |
) |
|
|
(123,158 |
) |
Long-term operating lease liabilities |
|
$ |
12,377 |
|
|
$ |
16,150 |
|
Note 6 –
Lessee Leases (continued)
Lease
maturities were as follows:
Schedule of lease
maturities
Maturity of lease liabilities |
|
|
|
|
|
|
12 months ending
September 30, |
|
Finance
leases |
|
|
Operating
leases |
|
2022 |
|
$ |
147,527 |
|
|
$ |
52,587 |
|
2023 |
|
|
136,233 |
|
|
|
12,377 |
|
2024 |
|
|
114,082 |
|
|
|
- |
|
2025 |
|
|
89,908 |
|
|
|
- |
|
2026 |
|
|
33,669 |
|
|
|
- |
|
Total |
|
|
521,419 |
|
|
|
64,964 |
|
Less:
Current maturities |
|
|
147,527 |
|
|
|
52,587 |
|
Long-term liability |
|
$ |
373,892 |
|
|
$ |
12,377 |
|
Note 7 –
Convertible notes
receivable
Convertible
notes receivable consists of the following:
Schedule of convertible notes
receivable
|
|
September 30,
2021
|
|
|
December 31,
2020
|
|
|
|
|
|
|
|
|
November 22, 2017, NeuCourt, Inc.
convertible note receivable including accrued interest of
$2,438
and $1,454
at September 30, 2021 and December 31, 2020. The note bears
interest at
5% per annum, originally matured
November 22, 2019, and was extended to mature
November 22, 2021. Principal and accrued interest are due at
maturity. Upon extension, the Company received a cash payment of
$2,496
for interest accrued through November 4, 2019.
Principal and unpaid interest may be converted into a blend of
shares of a to-be-created series of Preferred Stock and Common
Stock of NeuCourt (i) on closing of a future financing round of at
least $
750,000, (ii) on the election of NeuCourt on maturity of the
Note, or (iii) on election of Mentor following NeuCourt’s election
to prepay the Note. * |
|
$ |
27,102 |
|
|
$ |
26,454 |
|
|
|
|
|
|
|
|
|
|
October 31, 2018, NeuCourt, Inc. convertible note receivable
including accrued interest of $7,650
and $5,584
at September 30, 2021 and December 31, 2020. The note bears
interest at
5% per annum and matures
October 31, 2022. Principal and accrued interest are due at
maturity. Principal and unpaid interest
may be converted into a blend of shares of a to-be-created series
of Preferred Stock and Common Stock of NeuCourt (i) on closing of a
future financing round of at least $750,000,
(ii) on the election of NeuCourt on the maturity of the Note, or
(iii) on the election of Mentor following NeuCourt’s election to
prepay the Note. * |
|
|
57,985 |
|
|
|
55,584 |
|
|
|
|
|
|
|
|
|
|
Total convertible notes
receivable |
|
|
85,087 |
|
|
|
82,038 |
|
|
|
|
|
|
|
|
|
|
Less current
portion |
|
|
(27,102 |
) |
|
|
(26,454 |
) |
|
|
|
|
|
|
|
|
|
Long term
portion |
|
$ |
57,985 |
|
|
$ |
55,584 |
|
* |
The Conversion Price for
each Note is the lower of (i) 75% of the price paid in the Next
Equity Financing, or the price obtained by dividing a $3,000,000 valuation cap by the
fully diluted number of shares. The number of Conversion Shares
issued on conversion shall be the quotient obtained by dividing the
outstanding principal and unpaid accrued interest on a Note to be
converted on the date of conversion by the Conversion Price (the
“Total Number of Shares”), The Total Number of Shares shall consist
of Preferred Stock and Common Stock as follows: (i) That number of
shares of Preferred Stock obtained by dividing (a) the principal
amount of each Note and all accrued and unpaid interest thereunder
by (b) the price per share paid by other purchasers of Preferred
Stock in the Next Equity Financing (such number of shares, the
“Number of Preferred Stock”) and (ii) that number of shares of
Common Stock equal to the Total Number of Shares minus the Number
of Preferred Stock. Using the valuation cap of $3,000,000,
the November 22, 2017 Note would convert into 102,435
Conversion Shares and the October 31, 2018 Note would convert into
215,228
Conversion Shares at September 30, 2021. In the event of a
Corporate Transaction prior to repayment or conversion of the Note,
the Company shall receive back two times the outstanding principal
on the Note, plus all accrued unpaid interest. |
Note 8 –
Finance leases
receivable
Partner II
entered into a Master Equipment Lease Agreement with Pueblo West,
dated February 11, 2018, amended November 28, 2018 and March 12,
2019. Partner II acquired and delivered manufacturing equipment as
selected by Pueblo West under sales-type finance leases. Partner II
did not record any sales revenue for the nine months ended
September 30, 2021 and 2020. At September 30, 2021, all Partner II
leased equipment under finance leases receivable is located in
Colorado.
Performing
net finance leases receivable consisted of the
following:
Schedule of performing net
finance leases receivable
|
|
September 30, 2021 |
|
|
December 31, 2020 |
|
Gross minimum lease
payments receivable |
|
$ |
394,986 |
|
|
$ |
477,680 |
|
Accrued interest |
|
|
1,849 |
|
|
|
2,141 |
|
Less:
unearned interest |
|
|
(77,226 |
) |
|
|
(103,870 |
) |
Finance leases receivable |
|
|
319,609 |
|
|
|
375,951 |
|
Less current portion |
|
|
(72,789 |
) |
|
|
(69,053 |
) |
Long term portion |
|
$ |
246,820 |
|
|
$ |
306,898 |
|
Interest
income recognized on Partner II finance leases for the three months
ended September 30, 2021 and 2020 was $9,957
and
$11,730
respectively. Interest
income recognized on Partner II finance leases for the nine months
ended September 30, 2021 and 2020 was $31,176
and
$36,297,
respectively.
At September
30, 2021, minimum future payments receivable for performing finance
leases receivable were as follows:
Schedule of minimum future
payments receivable for performing finance leases
receivable
12
months ending September 30, |
|
Lease
Receivable |
|
|
Lease
Interest |
|
2022 |
|
$ |
79,275 |
|
|
$ |
32,163 |
|
2023 |
|
|
87,577 |
|
|
|
20,595 |
|
2024 |
|
|
96,747 |
|
|
|
11,425 |
|
2025 |
|
|
51,486 |
|
|
|
2,662 |
|
2026 |
|
|
8,804 |
|
|
|
336 |
|
Thereafter |
|
|
- |
|
|
|
- |
|
|
|
$ |
323,889 |
|
|
$ |
67,181 |
|
Note 9 -
Contractual interests
in legal recoveries
Interest in Electrum Partners, LLC
legal recovery
Electrum is
the plaintiff in that certain legal action captioned Electrum
Partners, LLC, Plaintiff, and Aurora Cannabis Inc., Defendant,
pending in the Supreme Court of British Columbia (“Litigation”). On
October 23, 2018, Mentor entered into a Joint Prosecution Agreement
among Mentor, Mentor’s corporate legal counsel, Electrum, and
Electrum’s legal counsel.
On October
30, 2018, Mentor entered into a Recovery Purchase Agreement
(“Recovery Agreement”) with Electrum under which Mentor purchased a
portion of Electrum’s potential recovery in the Litigation. Mentor
agreed to pay $100,000 of
costs incurred in the Litigation, in consideration for ten percent
(10%) of anything of value received by Electrum as a result of the
Litigation (“Recovery”) in addition to repayment of its initial
investment. As of September 30, 2021 and December 31, 2020, Mentor
invested an additional $81,529 of
capital in Electrum for payment of legal retainers and fees in
consideration for an additional eight percent (8%) of the Recovery.
At September 30, 2021 and December 31, 2020, the Recovery Agreement
investment is reported in the condensed consolidated balance sheets
at cost of $181,529 and $181,529, respectively. This
investment is subject to loss should Electrum not prevail in the
Litigation. However, Company management estimates that recovery is
more likely than not, and no impairment has been recorded at
September 30, 2021 and December 31, 2020.
Subsequent
to quarter end, the Company invested an additional $9,998 in Electrum’s Litigation
expenses, see Note 20 to the condensed consolidated financial
statements.
Note 9 -
Contractual interests in legal recoveries
(continued)
On October
31, 2018, Mentor also entered into a secured Capital Agreement with
Electrum under which Mentor invested an additional $100,000 of
capital in Electrum. In consideration for Mentor’s
investment, Electrum shall pay to Mentor, on the payment date, the
sum of (i) $100,000, (ii) ten percent of the Recovery, and (iii)
0.083334% of the Recovery for each full month from October 31, 2018
to the payment date for each full month that $833 is not paid to
Mentor. The payment date under the October 31, 2018 Capital
Agreement is the earlier of November 1, 2021, or the final
resolution of the Litigation. Payment is secured by all assets of
Electrum. This investment is included at cost of $100,000
in Contractual interests in legal recoveries on the
condensed consolidated balance sheets at September 30, 2021 and
December 31, 2020.
On January
28, 2019, Mentor entered into a second secured Capital Agreement
with Electrum. Under the second Capital Agreement, Mentor invested
an additional $100,000 of
capital in Electrum. In consideration for Mentor’s
investment, Electrum shall pay to Mentor on the payment date the
sum of (i) $100,000, (ii) ten percent (10%) of the Recovery, and
(iii) the greater of (A) 0.083334% of the Recovery for each full
month from January 28, 2019 until the payment date if the Recovery
occurs prior to the payment date, and (B) $833.34 for each full
month from January 28, 2019 until the payment date. The payment
date is the earlier of November 1, 2021, and the final resolution
of the Litigation. This investment is included at its $100,000
cost as part of the Contractual interests in legal recoveries on
the condensed consolidated balance sheets at September 30, 2021 and
December 31, 2020. In addition, the second Capital Agreement
provides that Mentor may, at any time up to and including 90 days
following the payment date, elect to convert its 6,198
membership interests in Electrum into a cash payment of $194,028 plus
an additional 19.4% of the Recovery.
Recovery on
this claim has been delayed due to COVID-19. The Company’s interest
in the Electrum Partners, LLC legal recovery, carried at cost, at
September 30, 2021 and December 31, 2020 is summarized as
follows:
Schedule of interest in legal
recovery carried at cost
|
|
September 30, 2021 |
|
|
December 31, 2020 |
|
October 30, 2018 Recovery Purchase
Agreement |
|
$ |
181,529 |
|
|
$ |
181,529 |
|
October 31, 2018 secured Capital Agreement |
|
|
100,000 |
|
|
|
100,000 |
|
January 28,
2019 secured Capital Agreement |
|
|
100,000 |
|
|
|
100,000 |
|
Total Invested |
|
$ |
381,529 |
|
|
$ |
381,529 |
|
Note 10 – Investments and fair
value
The
hierarchy of Level 1, Level 2 and Level 3 Assets are listed as
following:
Schedule
of hierarchy of level 1, level 2 and level 3
assets
|
|
Unadjusted Quoted Market Prices |
|
|
Quoted Prices for Identical or Similar
Assets in Active Markets |
|
|
Significant Unobservable
Inputs |
|
|
Significant Unobservable
Inputs |
|
|
Significant Unobservable
Inputs |
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value
Measurement Using |
|
|
|
Unadjusted Quoted Market
Prices |
|
|
Quoted Prices for
Identical or Similar Assets in Active Markets |
|
|
Significant Unobservable
Inputs |
|
|
Significant Unobservable
Inputs |
|
|
Significant Unobservable
Inputs |
|
|
|
(Level
1) |
|
|
(Level
2) |
|
|
(Level
3) |
|
|
(Level
3) |
|
|
(Level
3) |
|
|
|
Investment
in Securities |
|
|
|
|
|
Contractual
interest Legal Recovery |
|
|
Investment
in Common Stock Warrants |
|
|
Other Equity
Investments |
|
Balance at December 31, 2019 |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
346,195 |
|
|
$ |
5,669 |
|
|
$ |
204,028 |
|
Total gains or losses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in earnings (or changes in
net assets) |
|
|
(10,292 |
) |
|
|
- |
|
|
|
- |
|
|
|
(4,669 |
) |
|
|
- |
|
Purchases, issuances, sales, and
settlements |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases |
|
|
83,536 |
|
|
|
- |
|
|
|
50,717 |
|
|
|
- |
|
|
|
- |
|
Issuances |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Sales |
|
|
(38,418 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Settlements |
|
|
- |
|
|
|
- |
|
|
|
(15,383 |
) |
|
|
- |
|
|
|
- |
|
Balance at December 31, 2020 |
|
$ |
34,826 |
|
|
$ |
- |
|
|
$ |
381,529 |
|
|
$ |
1,000 |
|
|
$ |
204,028 |
|
Beginning balance |
|
$ |
34,826 |
|
|
$ |
- |
|
|
$ |
381,529 |
|
|
$ |
1,000 |
|
|
$ |
204,028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total gains or losses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in earnings (or changes in
net assets) |
|
|
(9000 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Purchases, issuances, sales, and
settlements |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases |
|
|
38,470 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuances |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Sales |
|
|
(42,913 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Settlements |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Balance at September 30,
2021 |
|
$ |
21,383 |
|
|
$ |
- |
|
|
$ |
381,529 |
|
|
$ |
1,000 |
|
|
$ |
204,028 |
|
Ending balance |
|
$ |
21,383 |
|
|
$ |
- |
|
|
$ |
381,529 |
|
|
$ |
1,000 |
|
|
$ |
204,028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 10 –
Investments and fair value (continued)
The
amortized costs, gross unrealized holding gains and losses, and
fair values of the Company’s investment securities classified as
equity securities, at fair value, at September 30, 2021 consists of
the following:
Schedule of amortized costs,
gross unrealized holding gains and losses, and fair values of
investment securities
Type |
|
Amortized
Costs |
|
|
Gross
Unrealized Gains |
|
|
Gross
Unrealized Losses |
|
|
Fair
Values |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NASDAQ listed company
stock |
|
$ |
38,470 |
|
|
$ |
17,087 |
|
|
$ |
- |
|
|
$ |
21,383 |
|
|
|
$ |
38,470 |
|
|
$ |
17,087 |
|
|
$ |
- |
|
|
$ |
21,383 |
|
The portion
of unrealized gains and losses for the period related to equity
securities still held at the reporting date is calculated as
follows:
Schedule of portion of
unrealized gains and losses related to equity
securities
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
|
Three Months
Ended September 30, |
|
|
Nine Months
Ended
September 30, |
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Net gains and losses
recognized during the period on equity securities |
|
$ |
(2,427 |
) |
|
$ |
(2,758 |
) |
|
$ |
9,001 |
|
|
$ |
(3,507 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: Net gains
(losses) recognized during the period on equity securities sold
during the period |
|
|
- |
|
|
|
- |
|
|
|
(2,508 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized
gains and losses recognized during the reporting period on equity
securities still held at the reporting date |
|
$ |
(2,427 |
) |
|
$ |
(2,758 |
) |
|
$ |
(6,493 |
) |
|
$ |
(3,507 |
) |
Note 11 -
Common stock
warrants
On August
21, 1998, the Company filed for voluntary reorganization with the
United States Bankruptcy Court for the Northern District of
California, and on January 11, 2000, the Company’s Plan of
Reorganization was approved. Among other things, the Company’s Plan
of Reorganization allowed creditors and claimants to receive new
Series A, B, C, and D warrants in settlement of their prior claims.
The warrants expire on May 11, 2038.
All Series
A, B, C, and D warrants have been called, and all Series A and C
warrants have been exercised. The Company intends to allow warrant
holders or Company designees, in place of original holders,
additional time as needed to exercise the remaining series B and D
warrants. The Company may lower the exercise price of all or part
of a warrant series at any time. Similarly, the Company could
reverse split the stock to raise the stock price above the warrant
exercise price. The warrants are specifically not affected and do
not split with the shares in the event of a reverse split. If the
called warrants are not exercised, the Company has the right to
designate the warrants to a new holder in return for a $0.10 per share
redemption fee payable to the original warrant holders. All such
changes in the exercise price of warrants were provided for by the
court in the Plan of Reorganization to provide a mechanism for all
debtors to receive value even if they could not or did not exercise
their warrant. Therefore, Management believes that the act of
lowering the exercise price is not a change from the original
warrant grants and the Company did not record an accounting impact
as the result of such change in exercise prices.
All Series A
and Series C warrants were exercised by December 31, 2014. Exercise
prices in effect at January 1, 2015 through September 30, 2021 for
Series B warrants were $0.11
and Series D warrants were $1.60.
Note 11 -
Common stock warrants (continued)
In 2009, the
Company entered into an Investment Banking agreement with Network 1
Financial Securities, Inc. and a related Strategic Advisory
Agreement with Lenox Hill Partners, LLC with regard to a potential
merger with a cancer development company. In conjunction with those
related agreements, the Company issued 689,159 Series H ($7)
Warrants, with a 30-year life. The warrants are subject
to cashless exercise based upon the ten-day trailing closing bid
price preceding the exercise as interpreted by the
Company.
As of
September 30, 2021 and December 31, 2020, the weighted average
contractual life for all Mentor warrants was 17
years and 17.5
years, respectively, and the weighted average outstanding warrant
exercise price was $0.17
and $2.11
per share, respectively.
During the
nine months ended September 30, 2021 and 2020, there were no warrants exercised and
there were no warrants issued. The
intrinsic value of outstanding warrants at September 30, 2021 and
December 31, 2020 was $0 and
$0,
respectively.
The
following table summarizes Series B and Series D common stock
warrants as of each period:
Schedule of common stock
warrants
|
|
Series B |
|
|
Series D |
|
|
B and D Total |
|
Outstanding at December 31, 2019 |
|
|
87,456 |
|
|
|
6,252,954 |
|
|
|
6,340,410 |
|
Issued |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Outstanding at December 31, 2020 |
|
|
87,456 |
|
|
|
6,252,954 |
|
|
|
6,340,410 |
|
Issued |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Exercised |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Outstanding at September 30,
2021 |
|
|
87,456 |
|
|
|
6,252,954 |
|
|
|
6,340,410 |
|
Series E, F,
G, and H warrants were issued for investment banking and advisory
services during 2009. Series E, F, and G warrants were exercised in
2014. The following table summarizes Series H ($7)
warrants as of each period:
|
|
Series
H
$7.00
exercise
price
|
|
Outstanding at December 31, 2019 |
|
|
689,159 |
|
Issued |
|
|
- |
|
Exercised |
|
|
- |
|
Outstanding at December 31,
2020 |
|
|
689,159 |
|
Outstanding balance |
|
|
689,159 |
|
|
|
|
|
|
Issued |
|
|
- |
|
Exercised |
|
|
- |
|
Outstanding at September 30,
2021 |
|
|
689,159 |
|
Outstanding balance |
|
|
689,159 |
|
On February
9, 2015, in accordance with Section 1145 of the United States
Bankruptcy Code and the Company’s Plan of Reorganization, the
Company announced a minimum 30-day partial redemption of up to 1%
(approximately 90,000) of the already outstanding Series D warrants
to provide for the court specified redemption mechanism for
warrants not exercised timely by the original holder or their
estates. Company designees that applied during the 30 days paid 10
cents per warrant to redeem the warrant and then exercised the
Series D warrant to purchase a share at the court specified formula
of not more than one-half of the closing bid price on the day
preceding the 30-day exercise period. In the Company’s October 7,
2016 press release, Mentor stated that the 1% redemptions which
were formerly priced on a calendar month schedule would
subsequently be initiated and be priced on a random date to be
scheduled after the prior 1% redemption is completed to prevent
potential third-party manipulation of share prices at month-end.
The periodic partial redemptions will continue to be periodically
recalculated and repeated until such unexercised warrants are
exhausted, or the partial redemption is otherwise paused, suspended
or truncated by the Company. For the nine months ended September
30, 2021 and 2020, no warrants were redeemed.
Note 12 -
Warrant redemption
liability
The Plan of
Reorganization provides the right for the Company to call, and the
Company or its designee to redeem warrants that are not exercised
timely, as specified in the Plan, by transferring a $0.10 redemption fee to the
former holders. Certain individuals desiring to become a Company
designee to redeem warrants have deposited redemption fees with the
Company that, when warrants are redeemed, will be forwarded to the
former warrant holders through DTCC or at their last known address
30 days after the last warrant of a class is exercised, or earlier
at the discretion of the Company. The Company has arranged for a
service to process the redemption fees in offset to an equal amount
of liability.
In prior
years the Series A, Series B, and Series C redemption fees have
been distributed through DTCC into holder’s brokerage accounts or
directly to the holders. All Series A and Series C warrants have
been exercised and are no longer outstanding. There are 87,456 Series B warrants
outstanding which are held by Chet Billingsley, the Company’s Chief
Executive Officer (“CEO”).
Once the
Series D warrants have been fully redeemed and exercised, the fees
for the Series D warrant series will likewise be distributed. Mr.
Billingsley has agreed to assume liability for paying these
redemption fees and therefore warrant redemption fees received are
retained by the Company for operating costs. Should Mr. Billingsley
be incapacitated or otherwise become unable to pay the warrant
redemption fees, the Company will remit the warrant redemption fees
to former holders from amounts due to Mr. Billingsley from the
Company, which are sufficient to cover the redemption fees at
September 30, 2021 and December 31, 2020.
Note 13 -
Stockholders’
equity
Common Stock
The Company
was incorporated in California in 1994 and was redomiciled as a
Delaware corporation, effective September 24, 2015. There are
75,000,000
authorized shares of Common Stock at $0.0001
par value. The holders of Common Stock are entitled to one vote per
share on all matters submitted to a vote of the
stockholders.
On August 8,
2014, the Company announced that it was initiating the repurchase
of 300,000
shares of its Common Stock (approximately 2% of the Company’s
common shares outstanding at that time). As of September 30, 2021
and December 31, 2020, 44,748 and
44,748 shares
have been repurchased and retired, respectively.
Preferred Stock
Mentor has
5,000,000,
$0.0001 par
value, preferred shares authorized.
On July 13,
2017, the Company filed a Certificate of Designation of Rights,
Preferences, Privileges and Restrictions of Series Q Preferred
Stock (“Certificate of Designation”) with the Delaware Secretary of
State to designate 200,000 preferred
shares as Series Q Preferred Stock, such series having a par value
of $0.0001 per share.
Series Q Preferred Stock is convertible into Common Stock, at the
option of the holder, at any time after the date of issuance of
such share and prior to notice of redemption of such share of
Series Q Preferred Stock by the Company, into such number of fully
paid and nonassessable shares of Common Stock as determined by
dividing the Series Q Conversion Value by the Conversion Price at
the time in effect for such share.
The per
share “Series Q Conversion Value,” as defined in the Certificate of
Designation, shall be calculated by the Company at least once each
calendar quarter as follows: The per share Series Q Conversion
Value shall be equal to the quotient of the “Core Q Holdings Asset
Value” divided by the number of issued and outstanding shares of
Series Q Preferred Stock. The “Core Q Holdings Asset Value” shall
equal the value, as calculated and published by the Company, of all
assets that constitute Core Q Holdings which shall include such
considerations as the Company designates and need not accord with
any established or commonly employed valuation method or
considerations. “Core Q Holdings” consists of all proceeds received
by the Company on the sale of shares of Series Q Preferred Stock
and all securities, acquisitions, and business acquired from such
proceeds by the Company. The Company shall periodically, but at
least once each calendar quarter, identify, update, account for and
value, the assets that comprise the Core Q Holdings.
Note 13 -
Stockholders’ equity (continued)
Preferred Stock
(continued)
The
“Conversion Price” of the Series Q Preferred Stock shall be at the
product of 105% and the closing price of the Company’s Common Stock
on a date designated and published by the Company. The Series Q
Preferred Stock is intended to allow for a pure play investment in
cannabis companies that have the potential to go public. The Series
Q Preferred Stock will be available only to accredited,
institutional or qualified investors.
The Company
sold and issued
11 shares of Series Q
Preferred Stock on May 30, 2018, at a price of $10,000
per share,
for an aggregate purchase price of $110,000
(“Series Q
Purchase Price”). The Company invested the Series Q Purchase Price
as capital in Partner II to purchase equipment to be leased to
Pueblo West. Therefore, the Core Q Holdings at September 30, 2021
and December 31, 2020 include this interest. The Core Q Holdings
Asset Value at September 30, 2021 and December 31, 2020 was
$17,455
and
$16,207
per share,
respectively. There is
no contingent liability for
the Series Q Preferred Stock conversion at September 30, 2021 and
December 31, 2020. At September 30, 2021 and December 31, 2020, the
Series Q Preferred Stock could have been converted at the
Conversion Price of $0.112
and
$0.085,
respectively, into an aggregate of
1,714,319 and
2,097,358 shares of the Company’s
Common Stock, respectively. Because there were net losses for the
three and nine month periods ended September 30, 2021 and 2020,
these shares were anti-dilutive and therefore are not included in
the weighted average share calculation for these
periods.
Note 14 -
Term
Loan
Term debt as
of September 30, 2021 and December 31, 2020 consists of the
following:
Schedule of term
debt
|
|
September 30,
2021 |
|
|
December 31, 2020 |
|
Bank of America auto
loan, interest at
2.37% per annum, monthly principal and interest payments of
$1,448,
maturing
December 2025, collateralized by vehicle. |
|
$ |
- |
|
|
$ |
81,812 |
|
|
|
|
|
|
|
|
|
|
Bank of America auto loan, interest
at
2.49% per annum, monthly principal and interest payments of
$1,505,
maturing
July 2025, collateralized by vehicle. |
|
|
65,816 |
|
|
|
- |
|
Less: Current maturities |
|
|
(15,099 |
) |
|
|
(15,566 |
) |
|
|
|
|
|
|
|
|
|
Long term
debt |
|
$ |
50,717 |
|
|
$ |
66,246 |
|
Note 15 –
Paycheck Protection
Program Loans and Economic Injury Disaster
Loans
Paycheck Protection Program
loans
In 2020, the
Company and WCI each received loans in the amount of $76,500 and $383,342, respectively, from the Bank of
Southern California and the Republic Bank of Arizona (collectively,
the “PPP Loans”). The PPP Loans were forgiven in November 2020,
except for $10,000 of WCI’s loan that was not
eligible for forgiveness due to receipt of a $10,000 Economic Injury Disaster Loan
Advance (“EIDL Advance”). However, on December 27, 2020, Section
1110(e)(6) of the CARES Act was repealed by Section 333 of the
Economic Aid Act. As a result, the SBA automatically remitted a
reconciliation payment to WCI’s PPP lender, the Republic Bank of
Arizona, for the previously deducted EIDL Advance amount, plus
interest through the remittance date. On March 16, 2021, The
Republic Bank of Arizona notified WCI of receipt of the
reconciliation payment and full forgiveness of the EIDL Advance.
The $10,000 forgiveness is reflected as
other income for the nine months ended September 30, 2021, in the
condensed consolidated income statements.
On February
17, 2021, Mentor received a second PPP Loan in the amount of
$76,593 (“Second PPP Loan”) pursuant to
Division N, Title III, of the Consolidated Appropriations Act, 2021
(the “Economic Aid Act”) as further set forth at Section 311 et.
seq. of the Economic Aid Act.
The Second
PPP Loan is forgivable so long as the borrower uses the loan
proceeds for eligible purposes, including payroll, benefits, rent,
utilities, and other covered operations expenditures, and maintains
its payroll levels. The amount of loan forgiveness will be reduced
if the borrower terminates employees or reduces salaries during the
forgiveness period.
Note 15 –
Paycheck Protection Program loans and Economic Injury Disaster Loan
(continued)
The Company
records PPP Loans as a liability in accordance with FASB ASC 470,
“Debt” and records accrued interest through the effective date of
forgiveness on the PPP Loans. Total gain on extinguishment of the
PPP Loans and accrued interest is reported in other income and
expense in the consolidated income statement.
PPP loan
balances consist of the following:
Schedule of paycheck protection
plan loan balances
|
|
September 30,
2021 |
|
|
December 31,
2020 |
|
May 5, 2020, PPP loan
from Republic Bank of Arizona to Waste Consolidators, Inc., revised
December 1, 2020. The note bears interest at 1% per annum, with a
revised maturation date of
May 15, 2020, with monthly principal and interest payments
of $560
beginning December 15, 2020. On March 16, 2021, WCI was notified of
full forgiveness of the note. |
|
$ |
- |
|
|
$ |
9,449 |
|
|
|
|
|
|
|
|
|
|
February 17,
2021, Second PPP loan from the Bank of Southern California, with
accrued interest of $473
at September 30, 2021. The loan bears interest at 1% per annum and
matures
January 16, 2026. Mentor may apply for forgiveness for
amounts disbursed for covered costs. Payment on any unforgiven
amount begins within ten months after last day of the loan
forgiveness covered period (i) beginning on the date that is 8
weeks after the date of disbursement and (ii) ending on the date
that is 24 weeks after the date of disbursement. Subsequent to
quarter end, on October 26, 2021, Mentor was notified of full
forgiveness of the note, see Note 20. |
|
|
77,066 |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Total |
|
|
77,066 |
|
|
|
9,449 |
|
|
|
|
|
|
|
|
|
|
Less: Current maturities |
|
|
- |
|
|
|
(6,658 |
) |
|
|
|
|
|
|
|
|
|
Long-term portion of paycheck protection plan loans |
|
$ |
77,066 |
|
|
$ |
2,791 |
|
Interest
expense on PPP Loans for the three months ended September 30, 2021
and 2020 was $194
and
$1,048,
respectively. Interest expense on PPP Loans for the nine months
ended September 30, 2021 and 2020 was $385
and
$1,798,
respectively.
Economic injury disaster
loan
On July 9,
2020, WCI received an additional Economic Injury Disaster Loan in
the amount of $150,000
through the
SBA. The loan is secured by all tangible and intangible personal
property of WCI, bears interest at
3.75% per annum, requires
monthly installment payments of $731
beginning
July 2021, and matures July 2050. The loan is
collateralized by all tangible and intangible assets of
WCI.
EIDL loan
balances at September 30, 2021 consist of the following:
Schedule of EIDL loan
balances
|
|
September 30,
2021 |
|
|
December 31,
2020 |
|
July 9, 2020, WCI
received an additional Economic Injury Disaster Loan, including
accrued interest of $5,513
and $2,502
as of September 30, 2021 and December 31, 2020, respectively. The
note is secured by all tangible and intangible personal property of
WCI, bears interest at
3.75% per annum, requires monthly installment payments of
$731
beginning July 2021, and matures
July 2050. |
|
$ |
156,862 |
|
|
$ |
152,602 |
|
|
|
|
|
|
|
|
|
|
Less: Current maturities* |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
Long-term portion of economic injury disaster loan |
|
$ |
156,862 |
|
|
$ |
152,602 |
|
* |
All payments through
March of 2023 will offset accrued interest incurred in the deferral
period and therefore the current maturity of principal is
$0
at September 30, 2021 and December 31, 2020. |
Interest
expense on the EIDL Loan for the three months ended September 30,
2021 and 2020 was $1,449 and $1,172, respectively.
Interest
expense on the EIDL Loan for the nine months ended September 30,
2021 and 2020 was $4,260 and $1,172, respectively.
Note 16 -
Accrued salary,
accrued retirement, and incentive fee - related
party
The Company
had an outstanding liability to its CEO as follows:
Schedule of outstanding
liability
|
|
September 30, 2021 |
|
|
December 31, 2020 |
|
Accrued salaries and
benefits |
|
$ |
873,013 |
|
|
$ |
848,796 |
|
Accrued retirement and other
benefits |
|
|
516,039 |
|
|
|
550,191 |
|
Offset by
shareholder advance |
|
|
(261,653 |
) |
|
|
(261,653 |
) |
Total
Outstanding Liabilities |
|
$ |
1,127,399 |
|
|
$ |
1,137,334 |
|
As approved
by resolution of the Board of Directors in 1998, the CEO will be
paid an incentive fee and a bonus which are payable in installments
at the CEO’s option. The incentive fee is 1% of the increase in
market capitalization based on the bid price of the Company’s stock
beyond the book value at confirmation of the bankruptcy, which was
approximately $260,000. The bonus is
0.5% of the increase in
market capitalization for each $1 increase in stock price up
to a maximum of $8 per share (4%) based on the bid
price of the stock beyond the book value at confirmation of the
bankruptcy. For the three and nine months ended September 30, 2021
and 2020, the incentive fee expense was $0 and $0,
respectively.
Note 17 –
Related party
transactions
On December
15, 2020, WCI received a $20,000
short term loan from an officer of WCI, which is reflected as a
related party payable at September 30, 2021 and December 31,
2020.
On March 12,
2021, Mentor received a $100,000 loan from
its CEO, which bears interest at 7.8% per annum compounded quarterly
and is due upon demand. On June 17, 2021, Mentor received an
additional $100,000 loan from
its CEO with the same terms as the previous loan. The loan from the
related party and accrued interest of $6,442 is
reflected as a long-term liability at September 30, 2021. For the
three months ended September 30, 2021 and 2020, the interest
expense on the long-term loan from the related party was $4,006 and
$0 respectively.
For the nine months ended September 30, 2021 and 2020, the interest
expense on the long-term loan from the related party was $6,442 and
$0
respectively.
Note 18 –
Commitments and
contingencies
G FarmaLabs
Limited, a Nevada corporation (“G Farma”) has not made scheduled
payments on the finance lease receivable or the notes receivable
summarized below since February 19, 2019. All amounts due from G
Farma are fully impaired at September 30, 2021 and December 31,
2020. A complete description of the agreements can be found in the
Company’s Annual Report for the period ended December 31, 2020 on
Form 10-K as filed with the SEC on April 15, 2021.
On March 17,
2017, the Company entered into a Notes Purchase Agreement with G
Farma, with operations in Washington that had planned operations in
California under two temporary licenses pending completion of its
Desert Hot Springs, California, location. Under the Agreement, the
Company purchased two secured promissory notes from G Farma in an
aggregate principal face amount of $500,000.
Subsequent to the initial investment, the Company executed eight
addenda. Addendum II through Addendum VIII increased the aggregate
principal face amount of the two notes to $1,100,000
and increased the combined monthly payments of the notes to
$10,239 per month beginning March
15, 2019 with a balloon payment on the notes of approximately
$894,172 due at
maturity.
On September
6, 2018, the Company entered into an Equity Purchase and Issuance
Agreement with G FarmaLabs Limited, G FarmaLabs DHS, LLC, GFBrands,
Inc., Finka Distribution, Inc., and G FarmaLabs, WA, LLC under
which Mentor was supposed to receive equity interests in the G
Farma Equity Entities and their affiliates (together, the “G Farma
Equity Entities”) equal to
3.75% of the G Farma Equity
Entities’ interests.
On March 4, 2019, Addendum VIII increased the G Farma Equity
Entities’ equity interest to which Mentor is immediately entitled
to 3.843%, and added Goya Ventures, LLC as a G Farma Equity
Entity. The G Farma Entities
failed to perform their obligations under the Equity Purchase and
Issuance Agreement and the equity investment
was fully impaired at September 30, 2021 and December 31,
2020.
Partner I
acquired and delivered manufacturing equipment as selected by the G
Farma Entities under sales-type finance leases. The finance leases
resulting from this investment have been fully impaired at
September 30, 2021 and December 31, 2020.
Note 18 –
Commitments and contingencies (continued)
On
May 28, 2019, the Company and Mentor
Partner I, LLC filed suit against the G Farma Entities and three
guarantors to the G Farma agreements, summarized above, in the
California Superior Court in and for the County of Marin. The
Company primarily sought monetary damages for breach of the G Farma
agreements, including promissory notes, leases, and other
agreements, to recover collateral under a security agreement and to
collect from guarantors on the agreements. The Company obtained, in
January 2020, a writ of possession to recover leased equipment
within G Farma’s possession. On January 31, 2020, all remaining
equipment leased to G Farma by Mentor Partner I was repossessed by
the Company. In the quarter ended June 30, 2020, the Company sold
all of the recovered equipment, with an original cost of $622,670,
for net proceeds of $249,481,
after deducting shipping and delivery costs. All proceeds from the
sale of repossessed equipment have been applied to the G Farma
lease receivable balance that is fully reserved at September 30,
2021 and December 30, 2020.
On November
4, 2020, the Court granted Mentor Capital, Inc.’s and Mentor
Partner I’s motion for summary adjudication as to both causes of
action against G FarmaLabs Limited for liability for breach of the
two promissory notes and one cause of action against each of Mr.
Gonzalez and Ms. Gonzalez related to their duties as guarantors of
G FarmaLabs Limited’s obligations under the promissory
notes.
On November 13,
2019, G Farma filed a Cross-Complaint for declaratory relief and
breach of contract relating to the consulting agreement between
Mentor and G Farma. The Company filed an answer on December 6,
2019, denying each and every allegation of the Cross-Complaint and
intends to vigorously defend itself in this
matter.
On August
27, 2021, the Company entered into a Settlement Agreement and
Mutual Release with the G Farma Entities to resolve and settle all
outstanding claims (“Settlement Agreement”). The Settlement Agreement
requires the G Farma Entities to pay the Company an aggregate of
$500,000
plus interest, payable monthly as follows: (i) $500 per month for
12 months beginning on September 5, 2021, (ii) $1,000 per month for
12 months beginning September 5, 2022, (iii) $2,000 per month for
12 months beginning September 5, 2023, and (iv) increasing by an
additional $1,000 per month on each succeeding September 5
thereafter, until the settlement amount and accrued unpaid interest
is paid in full. Interest on the unpaid balance shall initially
accrue at the rate of 4.25%, commencing February 25, 2021, and
shall be adjusted on February 25th of each year to equal
the Prime Rate as published in the Wall Street Journal plus
1%. In the event that the G Farma Entities fail to make any
monthly payment and have not cured such default within 10 days of
notice from the Company, the parties have stipulated that an
additional $2,000,000 will be
immediately added to the unpaid settlement amount payable by the G
Farma Entities.
The Company has retained the reserve on collections of the unpaid
lease receivable balance due to the long history of uncertain
payments from G Farma. See the Company’s Annual Report for the
period ended December 31, 2020 on Form 10-K, Footnotes 8 and 9, as
filed with the SEC April 15, 2021, for a discussion of the reserve
against the finance lease receivable.
Note 19 –
Segment
Information
The Company
is an operating, acquisition, and investment business. Subsidiaries
in which the Company has a controlling financial interest are
consolidated. The Company generally has two reportable segments; 1)
the cannabis and medical marijuana segment, which includes the cost
basis of membership interests of Electrum, the contractual interest
in the Electrum legal recovery, and the operation of subsidiaries
in the cannabis and medical marijuana sector; and 2) the Company’s
long standing investment in WCI which works with business park
owners, governmental centers, and apartment complexes to reduce
their facility-related operating costs. The Company also had small
investments in securities listed on the NYSE and NASDAQ, an
investment in note receivable from a non-affiliated party, the fair
value of convertible notes receivable and accrued interest from
NeuCourt, and the investment in NeuCourt that is included in the
Corporate, Other, and Eliminations section below. The NeuCourt
investments were previously reported as an investment that would be
useful in the cannabis space; however, NeuCourt has determined that
its legal services would likely be more useful to users outside of
the cannabis space. Prior period segment information presented
below contains reclassification of NeuCourt investments from the
cannabis and medical marijuana segment to the Corporate, other, and
eliminations segment.
Schedule of segment
information
|
|
Cannabis and
Medical Marijuana Segment |
|
|
Facility
Operations Related |
|
|
Corporate
and Eliminations |
|
|
Consolidated |
|
Three months ended September
30, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
9,972 |
|
|
$ |
1,482,649 |
|
|
$ |
- |
|
|
$ |
1,492,624 |
|
Operating income (loss) |
|
|
6,426 |
|
|
|
196,565 |
|
|
|
(116,664 |
) |
|
|
86,327 |
|
Interest income |
|
|
- |
|
|
|
- |
|
|
|
16,269 |
|
|
|
16,269 |
|
Interest expense |
|
|
- |
|
|
|
9,381 |
|
|
|
7,333 |
|
|
|
16,714 |
|
Property additions |
|
|
- |
|
|
|
92,013 |
|
|
|
1,264 |
|
|
|
93,277 |
|
Depreciation and amortization |
|
|
- |
|
|
|
13,570 |
|
|
|
1,461 |
|
|
|
15,031 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended September
30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
11,730 |
|
|
$ |
1,219,800 |
|
|
$ |
- |
|
|
$ |
1,231,530 |
|
Operating income (loss) |
|
|
4,516 |
|
|
|
(230,490 |
) |
|
|
(189,005 |
) |
|
|
(414,979 |
) |
Interest income |
|
|
8 |
|
|
|
- |
|
|
|
24,960 |
|
|
|
24,968 |
|
Interest expense |
|
|
- |
|
|
|
9,517 |
|
|
|
(1,004 |
) |
|
|
8,513 |
|
Property additions |
|
|
- |
|
|
|
6,490 |
|
|
|
2,581 |
|
|
|
9,071 |
|
Depreciation and amortization |
|
|
- |
|
|
|
3,892 |
|
|
|
2,038 |
|
|
|
5,930 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended September
30, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
31,176 |
|
|
$ |
4,154,711 |
|
|
$ |
- |
|
|
$ |
4,185,887 |
|
Operating income (loss) |
|
|
20,876 |
|
|
|
11,062 |
|
|
|
(417,644 |
) |
|
|
(385,706 |
) |
Interest income |
|
|
- |
|
|
|
- |
|
|
|
49,003 |
|
|
|
49,003 |
|
Interest expense |
|
|
- |
|
|
|
27,421 |
|
|
|
(23,032 |
) |
|
|
4,389 |
|
Property additions |
|
|
- |
|
|
|
107,290 |
|
|
|
1,264 |
|
|
|
108,554 |
|
Depreciation and amortization |
|
|
- |
|
|
|
29,923 |
|
|
|
4,382 |
|
|
|
34,305 |
|
Total assets |
|
|
396,907 |
|
|
|
1,997,786 |
|
|
|
2,153,940 |
|
|
|
4,548,633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine months ended September
30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
36,297 |
|
|
$ |
3,503,563 |
|
|
$ |
- |
|
|
$ |
3,539,860 |
|
Operating income (loss) |
|
|
(16,624 |
) |
|
|
(174,878 |
) |
|
|
(665,076 |
) |
|
|
(856,578 |
) |
Interest income |
|
|
- |
|
|
|
- |
|
|
|
65,504 |
|
|
|
65,504 |
|
Interest expense |
|
|
- |
|
|
|
25,829 |
|
|
|
(3,132 |
) |
|
|
22,697 |
|
Property additions |
|
|
- |
|
|
|
23,231 |
|
|
|
7,593 |
|
|
|
30,824 |
|
Depreciation and amortization |
|
|
- |
|
|
|
10,190 |
|
|
|
4,679 |
|
|
|
14,869 |
|
Total assets |
|
|
2,095,569 |
|
|
|
1,955,675 |
|
|
|
702,561 |
|
|
|
4,753,805 |
|
The
following table reconciles operating segments and
corporate-unallocated operating income (loss) to consolidated
income before income taxes, as presented in the unaudited condensed
consolidated income statements:
Schedule of reconciliation of
revenue from segments to consolidated
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
|
Three Months
Ended
September 30, |
|
|
Nine Months
Ended
September 30, |
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Operating loss |
|
$ |
86,327 |
|
|
$ |
(414,979 |
) |
|
$ |
(385,706 |
) |
|
$ |
(856,578 |
) |
Gain (loss) on investments |
|
|
(2,427 |
) |
|
|
(2,758 |
) |
|
|
(9,001 |
) |
|
|
(8,676 |
) |
Interest income |
|
|
16,269 |
|
|
|
24,968 |
|
|
|
49,003 |
|
|
|
65,504 |
|
Interest expense |
|
|
(16,714 |
) |
|
|
(8,513 |
) |
|
|
(43,899 |
) |
|
|
(22,697 |
) |
Gain on equipment disposals |
|
|
(671 |
) |
|
|
3,372 |
|
|
|
761 |
|
|
|
3,372 |
|
EIDL Advance |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
10,000 |
|
Other
income |
|
|
4,032 |
|
|
|
7,994 |
|
|
|
15,429 |
|
|
|
24,352 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 20 –
Subsequent
events
On October
6, 2021, the Company invested additional capital of $9,998
in Electrum
for Litigation costs pursuant to the Recovery Purchase Agreement.
The amount invested by the Company into Electrum for Litigation
costs has increased to $191,527
and the
Company is entitled to receive to 19% of anything of value received
by Electrum as a result of the Recovery, following reimbursement to
the Company of Litigation costs, see Note 9. Trial in the Electrum
Litigation is currently scheduled to commence on March 7,
2022.
On or about
October 26, 2021, the Company was notified of complete forgiveness,
effective October 26, 2021, of its $76,593 PPP Loan principal plus
accrued interest of $528.
Item 2. Management’s Discussion and
Analysis of Financial Condition and Results of
Operations.
The
following discussion will assist in the understanding of our
financial position at September 30, 2021 and the results of
operations for the nine months ended September 30, 2021 and 2020.
The information below should be read in conjunction with the
information contained in the unaudited Condensed Consolidated
Financial Statements and related notes to the financial statements
included within this Quarterly Report on Form 10-Q for the nine
months ended September 30, 2021 and 2020 and our Annual Report on
Form 10-K for the year ended December 31, 2020.
Corporate
Background
The
Company’s common stock trades publicly under the trading symbol
OTCQB: MNTR.
In 2009 the
Company began focusing its investing activities in leading-edge
cancer companies. In response to government limitations on
reimbursement for highly technical and expensive cancer treatments
and a resulting business decline in the cancer immunotherapy
sector, the Company decided to exit that space. In the summer of
2013, the Company was asked to consider investing in a
cancer-related project with a medical marijuana focus. On August
29, 2013, the Company decided to fully divest its cancer assets and
focus its next round of investments in the medical marijuana and
cannabis sector. In late 2019, the Company expanded its target
industry focus to potentially include energy, mining and minerals,
technology, consumer products, management services, and
manufacturing sectors with the goal of ensuring increased market
opportunities and investment diversification. In April 2021, the
Company announced that it is adding a cryptocurrency focus for
Mentor.
In September
2020, the Company moved its corporate office to Plano,
Texas.
Acquisitions and
investments
Waste
Consolidators, Inc. (WCI)
WCI is a
long standing investment of which the Company owns a 51% interest
and is included in the condensed consolidated financial statements
for the nine months ended September 30, 2021 and 2020. In the third
quarter of 2020, WCI began offering services in Houston, Texas.
This has led to an increase in selling, general and administrative
salaries as WCI positions itself to operate in this new
location.
Electrum
Partners, LLC (Electrum)
Electrum is
a Nevada based consulting, investment, and management company. The
Company’s equity interest in Electrum is reported in the condensed
consolidated balance sheets as an investment at cost of $194,028
and $194,028 at September 30, 2021 and December 31, 2020,
respectively. At September 30, 2021 and December 31, 2020, the
Company had approximately 6.69% and 6.69% interest of Electrum’s
outstanding equity, respectively.
On October
30, 2018, the Company entered into a Recovery Purchase Agreement
with Electrum to purchase a portion of Electrum’s potential
recovery in its legal action captioned Electrum Partners, LLC,
Plaintiff, and Aurora Cannabis Inc., Defendant, pending in the
Supreme Court of British Columbia (“Litigation”). As of September
30, 2021 and December 31, 2020, Mentor has provided $181,529 and
$181,529, respectively, in capital for payment of Litigation costs.
In exchange, after repayment to Mentor of all funds invested for
payment of Litigation costs, Mentor will receive 18% of anything of
value received by Electrum as a result of the Litigation
(“Recovery”). On October 31, 2018, Mentor entered into a secured
Capital Agreement with Electrum and invested an additional $100,000
in Electrum. Under the Capital Agreement, on the payment date,
Electrum will pay Mentor the sum of (i) $100,000, (ii) ten percent
(10%) of the Recovery, and (iii) 0.083334% of the Recovery for each
full month from October 31, 2018, to the payment date for each full
month that $833 is not paid to Mentor. The payment date for the
Capital Agreement is the earlier of November 1, 2021, or the final
resolution of the Litigation. On January 28, 2019, the Company
entered into a second secured Capital Agreement with Electrum and
invested an additional $100,000 in Electrum with payment terms
similar to the October 31, 2018 Capital Agreement. As part of the
January 28, 2019 Capital Agreement, Mentor was granted an option to
convert its 6,198 membership interests in Electrum into a cash
payment of $194,027.78 plus an additional 19.4% of the Recovery.
See Note 9 to the condensed consolidated financial
statements.
On October 6, 2021, the Company invested additional capital of
$9,998 in Electrum for Litigation costs pursuant to the Recovery
Purchase Agreement. The amount invested by the Company into
Electrum for Litigation costs has increased to $191,527 and the
Company is entitled to receive to 19% of anything of value received
by Electrum as a result of the Recovery, following reimbursement to
the Company of Litigation costs, see Note 9 to the condensed
consolidated financial statements. Trial in the Electrum Litigation
is currently scheduled to commence on March 7, 2022.
Mentor
IP, LLC (MCIP)
On April 18,
2016, the Company formed Mentor IP, LLC (“MCIP”), a South Dakota
limited liability company and wholly owned subsidiary of Mentor.
MCIP was formed to hold interests related to patent rights obtained
on April 4, 2016, when Mentor Capital, Inc. entered into that
certain “Larson - Mentor Capital, Inc. Patent and License Fee
Facility with Agreement Provisions for an — 80% / 20% Domestic
Economic Interest — 50% / 50% Foreign Economic Interest” with R. L.
Larson and Larson Capital, LLC (“MCIP Agreement”). Pursuant to the
MCIP Agreement, MCIP obtained rights to an international patent
application for foreign THC and CBD cannabis vape pens under the
provisions of the Patent Cooperation Treaty of 1970, as amended. R.
L. Larson continues its efforts to obtain exclusive licensing
rights in the United States for THC and CBD cannabis vape pens for
various THC and CBD percentage ranges and concentrations. Activity
is currently limited to the annual payment of patent maintenance
fees in Canada. On January 21, 2020, the United States Patent and
Trademark Office granted a Notice of Allowance for the United
States patent application, and on May 5, 2020, the United States
patent was issued. On June 29, 2020, the Canadian Intellectual
Property Office granted a Notice of Allowance for the Canada
patent, and on September 22, 2020, the Canadian patent was issued.
Patent application national phase maintenance fees were expensed
when paid, and therefore, no capitalized assets related to MCIP are
reported on the condensed consolidated financial statements at
September 30, 2021 and December 31, 2020.
NeuCourt,
Inc.
NeuCourt,
Inc. is a Delaware corporation that is developing a technology that
is expected to be useful to the dispute resolution
industry.
On November
22, 2017, the Company invested $25,000 in NeuCourt, Inc.
(“NeuCourt”) as a convertible note receivable. The note bears
interest at 5% per annum, originally matured November 22, 2019, and
was amended to extend the maturity date to November 22, 2021. No
payments are required prior to maturity. However, at the time the
November 22, 2017 note was extended, interest accrued through
November 4, 2019, was remitted to Mentor. As consideration for the
extension of the maturity date for the $25,000 note, a warrant to
purchase up to 25,000 shares of NeuCourt common stock at $0.02 per
share was issued to Mentor.
On October
31, 2018, the Company invested an additional $50,000 as a
convertible note receivable in NeuCourt, which bears interest at
5%, originally matured October 31, 2020, and was amended to extend
the maturity date to October 31, 2022. As consideration for the
extension of the maturity date for the $50,000 note plus accrued
interest of $5,132, a warrant to purchase up to 52,500 shares of
NeuCourt common stock at $0.02 per share was issued to Mentor.
Principal and unpaid interest on the Notes may be converted into a
blend of shares of a to-be-created series of Preferred Stock and
Common Stock of NeuCourt (i) on the closing of a future financing
round of at least $750,000, (ii) on the election of NeuCourt on the
maturity of the Note, or (iii) on the election of Mentor following
NeuCourt’s election to prepay the Note.
On December
21, 2018, the Company purchased 500,000 shares of NeuCourt Common
Stock for $10,000. This represents approximately 6.1% of the issued
and outstanding NeuCourt shares at September 30, 2021.
Mentor
Partner I, LLC
On September
19, 2017, the Company formed Mentor Partner I, LLC (“Partner I”), a
California limited liability company as a wholly owned subsidiary
of Mentor. Partner I has subsequently been reorganized under the
laws of the State of Texas. In 2018 and 2019, Mentor contributed
$1,010,326 of capital to Partner I to facilitate the purchase of
manufacturing equipment to be leased from Partner I by G FarmaLabs
Limited (“G Farma”) under a Master Equipment Lease Agreement dated
January 16, 2018, as amended. Amendments expanded the Lessee under
the agreement to include G FarmaLabs Limited and G FarmaLabs DHS,
LLC (collectively referred to as “G Farma Lease Entities”). The
finance leases resulting from this investment have been fully
impaired at September 30, 2021 and December 31, 2020. Management
considers collection on the leases to be unlikely, see Note 18 to
the condensed consolidated financial statements.
Mentor
Partner II, LLC
On February
1, 2018, the Company formed Mentor Partner II, LLC (“Partner II”),
a California limited liability company, as a wholly owned
subsidiary of Mentor. Partner II has subsequently reorganized under
the laws of the State of Texas. On February 8, 2018, Mentor
contributed $400,000 to Partner II to facilitate the purchase of
manufacturing equipment to be leased from Partner II by Pueblo West
under a Master Equipment Lease Agreement dated February 11, 2018,
as amended see Note 8 to the condensed consolidated financial
statements. On March 12, 2019, Mentor agreed to use Partner II’s
earnings of $61,368 to facilitate the purchase of additional
manufacturing equipment to Pueblo West under a Second Amendment to
the lease, see Note 8 to the condensed consolidated financial
statements. Payment on the leases are current.
Overview
The Company
expanded its target industry focus, beginning in the third quarter
of 2019, from its investment in WCI and investments in the medical
marijuana and social use cannabis sector to include energy, mining
and minerals, technology, consumer products, management services,
and manufacturing sectors with the goal of ensuring increased
market opportunities and investment diversification. In April 2021,
the Company announced that it is adding a cryptocurrency focus. Our
general business operations are intended to provide management
consultation and headquarters functions, especially with regard to
accounting and audits, for our larger investment targets and our
majority-owned subsidiaries. We monitor our smaller and less than
majority positions for value and investment security. Management
also spends considerable effort reviewing possible acquisition
candidates on an ongoing basis.
Mentor seeks
to take significant positions in the companies it invests in to
provide public market liquidity for founders, protection for
investors, funding for the companies, and to incubate private
companies that Mentor believes to have significant potential. When
Mentor takes a significant position in its investees, it provides
financial management when needed but leaves operating control in
the hands of the company founders. Retaining control, receiving
greater liquidity, and working with an experienced organization to
efficiently develop disclosures and compliance are three potential
key advantages to founders working with Mentor Capital,
Inc.
Because
adult social use and medical marijuana opportunities often overlap,
Mentor Capital has participated in the ancillary side of the legal
recreational marijuana market. However, Mentor’s preferred focus
was medical, and the Company sought to facilitate the application
of cannabis to cancer wasting, Parkinson’s disease, calming
seizures, reducing ocular pressures from glaucoma, and blunting
chronic pain.
Business
Segments
We generally
manage our operations through two operating segments, cannabis and
medical marijuana segment and our long-standing investment in WCI.
WCI works with business park owners, governmental centers, and
apartment complexes in Arizona and Texas to reduce their
facilities’ operating costs. In late 2019, Mentor expanded its
target industry focus to potentially include energy, mining and
minerals, technology, consumer products, management services, and
manufacturing sectors with the goal of ensuring increased market
opportunities and investment diversification. In April 2021, the
Company announced that it is adding a cryptocurrency
focus.
Liquidity
and Capital Resources
The
Company’s future success is dependent upon its ability to make a
return on its investments, to generate positive cash flow, and to
obtain sufficient capital from non-portfolio-related sources.
Management believes they have approximately twelve months of
operating resources on hand and can raise additional funds as may
be needed to support their business plan and develop an operating,
cash flow positive company.
Results
of Operations
Three Months Ended September 30, 2021,
compared to Three Months Ended September 30,
2020
Revenues
Revenue for
the three months ended September 30, 2021 was $1,492,624 compared
to $1,231,530 for the three months ended September 30, 2020 (“the
prior year period”), an increase of $261,094 or 21.2%. This
increase is due to a $262,801 increase in WCI service
fees.
Gross
profit
Gross profit
for the three months ended September 30, 2021 was $488,584 compared
to $375,735 for the prior year period. Cost of goods sold relate to
WCI and Partner II. WCI experienced gross profit of $478,609 or
32.3% of revenue for the three months ended September 30, 2021,
compared to $364,004 or 29.8% for the prior year period, an
increase of $114,605 with an increase of 2.5% in gross profit as a
percentage of revenue. Partner II had gross profit of $9,975 for
the three months ended September 30, 2021 as compared to $11,730 in
the prior year period. Partner I did not have revenue for the three
months ended September 30, 2021 and 2020.
The increase
in WCI gross profit percentage was due largely to revenue
increasing at a higher rate (29.8%) than costs of goods sold
(17.3%). Labor and related costs increased by $105,204 or 19.2%
over the prior year period. Other costs of goods sold increased by
$43,050 or 14%. compared to the third quarter of 2020, which
represents a 19.7% decrease.
Selling, general
and administrative expenses
Our selling,
general and administrative expenses for the three months ended
September 30, 2021 was $402,255 compared to $790,714 for the prior
year period, a decrease of $388,459. We experienced a decrease of
($72,497) in salary and wages, and a decrease of ($320,841) in
management fees, partially offset by an increase of $8,642 in
professional fees, an increase of $7,000 in bad debt expense, and
an increase in office expense of $5,642 for the three months ended
September 30, 2021 as compared to the prior year period.
Other
income and expense
Other income
and expense, net, totaled $489 for the three months ended September
30, 2021 compared to $25,063 for the prior year period, a decrease
of ($24,574). We experienced increases of $87,393 in WCI
non-controlling interest, $671 in losses on disposal of right of
use assets and ($16,714) in interest expense. We experienced
decreases of ($1,427) in gain on investment securities, ($16,269)
in interest income, and ($3,032) in other miscellaneous income and
expense
Net
results
The net
result for the three months ended September 30, 2021 was a net loss
attributable to Mentor of ($3,390) or ($0.000) per Mentor common
share compared to a net loss attributable to Mentor in the prior
year period of ($273,955) or ($0.012) per Mentor common share.
Management will continue to make an effort to lower operating
expenses and increase revenue and gross margin. The Company will
continue to look for acquisition opportunities to expand its
portfolio in companies that are positive for operating revenue or
have the potential to become positive for operating
revenue.
Nine months Ended September 30, 2021,
compared to Nine months Ended September 30,
2020
Revenues
Revenue for
the nine months ended September 30, 2021 was $4,154,711 compared to
$3,539,860 for the nine months ended September 30, 2020 (“the prior
year period”), an increase of $646,027 or 18.3%. This increase is
due to a $651,148 increase in WCI service fees, partially offset by
a ($5,121) decrease in finance lease revenue in the current period
as compared to the prior year period.
Gross
profit
Gross profit
for the nine months ended September 30, 2021 was $1,303,612
compared to $1,120,659 for the prior year period. Cost of goods
sold relate to WCI and Partner II. WCI experienced gross profit of
$1,276,462 or 30.7% of revenue for the nine months ended September
30, 2021, compared to $1,084,362 or 31.0% for the prior year
period, an increase of $27,150 with a decrease of 0.3% as a
percentage of revenue. Partner II had gross profit of $31,176 for
the nine months ended September 30, 2021 as compared to
$36,297.
The decrease
in WCI gross profit percentage was due to an increase in labor and
related costs of 19.1%, an increase of 18.0% in disposal costs and
an increase of 113.8% in Right of Use Asset amortization over the
prior year period. These increases were partially offset by an
increase of (18.6%) in revenue, over the prior year
period.
Selling, general
and administrative expenses
Our selling,
general and administrative expenses for the nine months ended
September 30, 2021 were $1,689,317 compared to $1,977,237 for the
prior year period, a decrease of $287,920. We experienced a
decrease of $163,699 in salary and wages, and a decrease of
$100,841 in professional fees, partially offset by an increase of
$33,227 in office expense, an increase of $133,227 in outside
services, for the nine months ended September 30, 2021 as compared
to the prior year period.
Other
income and expense
Other income
and expense, net, totaled $12,293 for the nine months ended
September 30, 2021 compared to $71,855 for the prior year period, a
decrease of $59,562. WCI received a $10,000 EIDL Advance in the
prior nine-month period. Of the decrease, $21,202 is due to an
increase in interest expense of $43,899 in the current year period
compared to $22,697 in the prior year period. The decrease was also
partially due to a decrease in interest income of $16,501 and a
decrease in other miscellaneous income of $19,923. This was offset
by forgiveness of WCI’s $10,000 EIDL Advance during the current
nine-month period.
Net
results
The net
result for the nine months ended September 30, 2021 was a net loss
attributable to Mentor of ($366,934) or ($0.016) per Mentor common
share compared to a net loss attributable to Mentor in the prior
year period of ($705,910) or ($0.031) per Mentor common share.
Management will continue to make an effort to lower operating
expenses and increase revenue and gross margin. The Company will
continue to look for acquisition opportunities to expand its
portfolio in companies that are positive for operating revenue or
have the potential to become positive for operating
revenue.
Liquidity and
Capital Resources
Since our
reorganization, we have raised capital through warrant holder
exercise of warrants to purchase shares of Common Stock. At
September 30, 2021 we had cash and cash equivalents of $278,068 and
working capital of $623,786. These factors raise substantial doubt
about the Company’s ability to continue as a going
concern.
Operating
cash outflows in the nine months ended September 30, 2021 was
($343,709), including ($381,977) of net loss, less noncash
forgiveness of PPP loan of ($10,000), less non-cash amortization of
discount on our investment in account receivable of ($45,684), less
an increase in accrued interest income of ($3,049), plus a loss on
an investment in securities of $9,001, and a decrease in operating
assets of ($134,220), partially offset by non-cash depreciation and
amortization of $34,305, non-cash amortization on right of use
assets of $111,307, non-cash bad debt expense of $19,580, loss on
right of use asset disposal of $643, and a $57,789 increase in
operating liabilities.
Cash
outflows from investing activities in the nine months ended
September 30, 2021 were ($59,468) due to purchase and sale of
investment securities netting to $4,442, purchase and sale of
property and equipment netting to ($17,173), and down payments on
right of use assets of ($46,737).
Net inflows
from financing activities during the nine months ended September
30, 2021 were $175,071 consisting of proceeds from related party
loan of $204,006, proceeds from Paycheck Protection Program loans
of $76,593, and refund of payment on Paycheck Protection Program
loans of $551. Cash outflows from financing activities include
payments on long-term debt of ($15,996) and ($90,082) of payments
on finance lease liabilities.
We will be
required to raise additional funds through financing, additional
collaborative relationships or other arrangements until we are able
to raise revenues to a point of positive cash flow.
In addition,
on February 9, 2015, in accordance with Section 1145 of the United
States Bankruptcy Code and the Company’s court-approved Plan of
Reorganization, the Company announced a minimum 30 day partial
redemption of up to 1% of the already outstanding Series D warrants
to provide for the court specified redemption mechanism for
warrants not exercised timely by the original holder or their
estates. Company designees that applied during the 30 days paid 10
cents per warrant to redeem the warrant and then exercised the
Series D warrant to purchase a share at the court specified formula
of not more than one-half of the closing bid price on the day
preceding the 30 day exercise period. In the Company’s October 7,
2016 press release, Mentor stated that the 1% redemptions which
were formerly priced on a calendar month schedule would
subsequently be initiated and be priced on a random date to be
scheduled after the prior 1% redemption is completed to prevent
potential third party manipulation of share prices at month-end.
The periodic partial redemptions may continue to be recalculated
and repeated until such unexercised warrants are exhausted, or the
partial redemption is otherwise temporarily paused, suspended, or
truncated by the Company.
For the nine
months ended September 30, 2021, there were no redemptions of
Series D Warrants. There were no redemptions of Series D Warrants
in 2020. We believe that if warrants are redeemed and exercised,
partial warrant redemptions would provide monthly cash in excess of
what is required for monthly operations for an extending period of
time while we are exploring other major sources of funding for
further acquisitions.
Disclosure
About Off-Balance Sheet Arrangements
We do not
have any transactions, agreements, or other contractual
arrangements that constitute off-balance sheet
arrangements.
Item 3. Quantitative and
Qualitative Disclosures About Market Risk.
As a
“smaller reporting company” as defined in Rule 12b-2 of the
Exchange Act, we are not required to provide the information called
for by this item.
Item 4. Controls and
Procedures.
Evaluation of
disclosure controls and procedures
Management,
with the participation of our chief executive officer and principal
financial officer, evaluated the effectiveness of our disclosure
controls and procedures pursuant to Rule 13a-15 under the Exchange
Act. In designing and evaluating the disclosure controls and
procedures, management recognizes that any controls and procedures,
no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives.
In addition, the design of disclosure controls and procedures must
reflect the fact that there are resource constraints and that
management is required to apply its judgment in evaluating the
benefits of possible controls and procedures relative to their
costs.
Based on
management’s evaluation, our chief executive officer and principal
financial officer concluded that, as of September 30, 2021, our
disclosure controls and procedures are designed at a reasonable
assurance level and are effective to provide reasonable assurance
that information we are required to disclose in reports that we
file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in SEC
rules and forms and that such information is accumulated and
communicated to our managers, including our chief executive officer
and principal financial officer, as appropriate, to allow timely
decisions regarding required disclosure.
Changes
in internal control over financial reporting.
We regularly
review our system of internal control over financial reporting and
make changes to our processes and systems to improve controls and
increase efficiency while ensuring that we maintain an effective
internal control environment. Changes may include such activities
as implementing new, more efficient systems, consolidating
activities, and migrating processes.
There were
no changes in our internal control over financial reporting that
occurred during the quarter ended September 30, 2021 that have
materially affected or are reasonably likely to materially affect
our internal control over financial reporting.
PART II – OTHER
INFORMATION
Item 1. Legal
Proceedings.
G FarmaLabs
Limited
On May 28,
2019, Mentor Capital, Inc. and Mentor Partner I, LLC filed a
complaint in the Superior Court of California in the County of
Marin for, among other things, breach of contract against G
FarmaLabs Limited, Atanachi (“Ata”) Gonzalez, Nicole Gonzalez, G
FarmaLabs DHS, LLC, GFBrands, Inc., fka G FarmaBrands, Inc., Finka
Distribution, Inc., G FarmaLabs WA, LLC, and Goya Ventures, LLC
(together “Defendants”). Under the complaint, among other
things:
|
● |
Mentor
Capital, Inc. alleged that G FarmaLabs Limited and Ata Gonzalez and
Nicole Gonzalez as guarantors of the G Farma obligations failed to
perform their several obligations under a Note Purchase Agreement
and two secured Promissory Notes dated March 17, 2017, as amended.
At December 31, 2019, the aggregate amount due, owing, and unpaid
under both Notes is $1,045,051. Interest of approximately $67,770
was also due but was not accrued in the financial statements due to
uncertainty of collection. |
|
● |
Mentor
Partner I, LLC alleged that G FarmaLabs Limited, G FarmaLabs DHS,
LLC as Lessees and GFBrands, Inc, Ata Gonzalez, and Nicole Gonzalez
as guarantors of the lease obligations failed to perform their
several obligations under a Master Equipment Lease dated January
16, 2018, as amended. At December 31, 2019, the aggregate amount
due, owing, and unpaid under the Lease is $1,055,680. Interest of
approximately $93,710 was also due but was not accrued in the
financial statements due to uncertainty of collection. |
|
● |
Mentor
Capital, Inc. also alleged that the G FarmaLabs Limited and Ata
Gonzalez and Nicole Gonzalez as guarantors failed to perform their
obligations under (i) a Consulting Agreement dated March 17, 2017,
as amended, (ii) a Rights Agreement dated March 17, 2017, and (iii)
a Security Agreement dated March 17, 2017, as amended. |
|
● |
Mentor
Capital, Inc. also alleged that G FarmaLabs Limited, G FarmaLabs
DHS, LLC, GFBrands, Inc., Finka Distribution, Inc., G FarmaLabs WA,
LLC, and Goya Ventures, LLC failed to perform their obligations
under an Equity Purchase and Issuance Agreement dated September 6,
2018, as amended. |
|
● |
Mentor
Capital, Inc. and Mentor Partner I, LLC sought an injunction
against all Defendants preventing Defendants from keeping equipment
leased under the Master Lease Agreement. |
On or about
November 13, 2019, G FarmaLabs Limited, Ata Gonzales, and Nicole
Gonzales filed a cross-complaint against Mentor Capital, Inc.
alleging breach of contract related to the Consulting Agreement
dated March 17, 2017, and seeking declaratory relief related to the
validity of the agreements between the parties. Mentor Capital,
Inc. filed its answer to the cross-complaint on December 6,
2019.
On January
31, 2020, following the Court’s grant of the Company’s motion for a
writ of possession, all equipment leased to G Farma by Mentor
Partner I, was repossessed by the Company. Repossessed equipment
with a cost of $622,670 was sold in 2020 to the highest offerors
for net proceeds of $249,481, after shipping and delivery costs,
which proceeds were applied against the lease receivable balance
that is fully reserved at September 30, 2021 and December 31,
2020.
On November
4, 2020, the Court granted Mentor Capital, Inc.’s and Mentor
Partner I’s motion for summary adjudication as to both causes of
action against G FarmaLabs Limited for liability for breach of the
two promissory notes and one cause of action against each of Mr.
Gonzalez and Ms. Gonzalez related to their duties as guarantors of
G FarmaLabs Limited’s obligations under the promissory
notes.
On August
27, 2021, the Company entered into a Settlement Agreement and
Mutual Release with the G Farma Entities to resolve and settle all
outstanding claims (“Settlement Agreement”). The Settlement
Agreement requires the G Farma Entities to pay the Company an
aggregate of $500,000 plus interest, payable monthly as follows:
(i) $500 per month for 12 months beginning on September 5, 2021,
(ii) $1,000 per month for 12 months beginning September 5, 2022,
(iii) $2,000 per month for 12 months beginning September 5, 2023,
and (iv) increasing by an additional $1,000 per month on each
succeeding September 5 thereafter, until the settlement amount and
accrued unpaid interest is paid in full. Interest on the unpaid
balance shall initially accrue at the rate of 4.25%, commencing
February 25, 2021, and shall be adjusted on February
25th of each year to equal the Prime Rate as published
in the Wall Street Journal plus 1%. In the event that the G Farma
Entities fail to make any monthly payment and have not cured such
default within 10 days of notice from the Company, the parties have
stipulated that an additional $2,000,000 will be immediately added
to the unpaid settlement amount payable by the G Farma
Entities.
Item 1A. Risk
Factors.
In addition
to other information in this Quarterly Report on Form 10-Q, the
following risk factors should be carefully considered in evaluating
our business since it operates in a highly changing and complex
business environment that involves numerous risks, some of which
are beyond our control. The following discussion highlights a few
of these risk factors, any one of which may have a significant
adverse impact on our business, operating results, and financial
condition.
As a result
of the risk factors set forth below and elsewhere in this Form 10-Q
and in our Form 10-K, and the risks discussed in our Rule 15c2-11
and other publicly disclosed submissions, actual results could
differ materially from those projected in any forward-looking
statements.
We face
significant risks, and the risks described below may not be the
only risks we face. Additional risks that we do not know of or that
we currently consider immaterial may also impair our business
operations. If any of the events or circumstances described in the
following risks actually occurs, our business, financial condition
or results of operations could be harmed, and the trading price of
our Common Stock could decline.
We may
not be able to continue as a going concern.
Management
has noted certain financial conditions that raise substantial
doubts about the Company’s ability to continue as a going concern.
During the nine months ended September 30, 2021, and years ended
December 31, 2020 and 2019, we experienced significant operating
losses, liquidity constraints, and negative cash flows from
operations. If we are unable to make a return on our investments to
generate positive cash flow and cannot obtain sufficient capital
from non-portfolio-related sources to fund operations and pay
liabilities in a timely manner, we may have to cease our
operations. Securing additional sources of financing to enable us
to continue investing in our target markets will be difficult, and
there is no assurance of our ability to secure such financing. A
failure to obtain additional financing and generate positive cash
flow from operations could prevent us from making expenditures that
are needed to pay current obligations, allow us to hire additional
personnel, and continue to seek out and invest in new companies.
This leaves doubt as to our ability to continue as a going
concern.
A
failure to obtain financing could prevent us from executing our
business plan or operate as a going concern
We
anticipate that current cash resources and opportunities will be
sufficient for us to execute our business plan for twelve months
after the date these financial statements are issued. It is
possible that if future financing is not obtained, we will not be
able to operate as a going concern. We believe that securing
substantial additional sources of financing is possible, but there
is no assurance of our ability to secure such financing. A failure
to obtain additional financing could prevent us from making
necessary expenditures for advancement and growth to partner with
businesses and hire additional personnel. If we raise additional
financing by selling equity, or convertible debt securities, the
relative equity ownership of our existing investors could be
diluted, or the new investors could obtain terms more favorable
than previous investors. If we raise additional funds through debt
financing, we could incur significant borrowing costs and be
subject to adverse consequences in the event of a
default.
Management
voluntarily transitioned to a fully reporting company and spends
considerable time meeting the associated reporting
obligations.
Management
operated Mentor Capital, Inc. as a non-reporting public company for
over 26 years and voluntarily transitioned to reporting company
status subject to financial and other SEC-required disclosures.
Prior to such voluntary transition, management had not been
required to prepare and make such required disclosures. As a
reporting company, we may be subject to certain reporting
requirements of the Securities Exchange Act of 1934, as amended
(“Exchange Act”), the Sarbanes-Oxley Act, the Dodd-Frank Act, the
listing requirements of a national securities exchange, and other
applicable securities rules and regulations. The Exchange Act
requires, among other things, that we file annual, quarterly, and
current reports with respect to our business and operating
activities. Preparing and filing periodic reports imposes a
significant expense, time, and reporting burden upon management.
This distraction can divert management from its operation of the
business to the detriment of core operations. Also, inadvertent
improper reporting due to Mentor’s officers’ limited reporting
experience can result in trading restrictions and other sanctions
that may impair or even suspend trading in the Company’s Common
Stock.
Investors may
suffer risk of dilution following exercise of warrants for
cash.
As of
September 30, 2021, the Company had 22,850,947 outstanding shares
of its Common Stock trading at approximately $0.11. As of the same
date, the Company also had 6,252,954 outstanding Series D warrants
exercisable for shares of Common Stock at $1.60 per share. These
Series D warrants do not have a cashless exercise feature. The
Company anticipates that the warrants may be increasingly exercised
anytime the per share price of the Company’s Common Stock is
greater than $1.60 per share. Exercise of these Series D warrants
may result in immediate and potentially substantial dilution to
current holders of the Company’s Common Stock. At September 30,
2021, there were 87,456 Series B warrants exercisable at $0.11 that
do not have a cashless exercise feature. In addition, the Company
has 689,159 outstanding Series H warrants with a per share exercise
price of $7.00 held by an investment bank and its affiliates. These
$7.00 Series H warrants include a cashless exercise feature.
Current and future shareholders may suffer dilution of their
investment and equity ownership if any of the warrant holders elect
to exercise their warrants.
Beginning on
February 9, 2015, in accordance with Section 1145 of the United
States Bankruptcy Code and in accordance with the Company’s
court-approved Plan of Reorganization, the Company announced that
it would allow for partial redemption of up to 1% per month of the
outstanding Series D warrants to provide for the court specified
redemption mechanism for warrants not exercised timely by the
original holder or their estates. On October 7, 2016, the Company
announced that the 1% redemptions which were formerly priced on a
calendar month schedule would subsequently be initiated and priced
on a random date to be scheduled after the prior 1% redemption is
complete to prevent potential third-party manipulation of share
prices during the pricing period at month-end. Company designees
that apply during the redemption period must pay 10 cents per
warrant to redeem the warrants and then exercise the Series D
warrant to purchase a share of the Company’s Common Stock at a
maximum of one-half of the closing bid price on the day preceding
the 1% partial redemption. The 1% partial redemption may continue
to be periodically recalculated and repeated according to the court
formula until such unexercised warrants are exhausted, or the
partial redemption is otherwise suspended or truncated by the
Company. There were no warrant redemptions in the first quarter of
2021 or in fiscal 2020.
We
operate in a turbulent markets populated by businesses that are
highly volatile.
The U.S.
market for cannabis products is highly volatile. While we believe
that it is an exciting and growing market, many companies involved
in cannabis products and services used to be involved in illegal
activities, some still are, and many of them operate in
unconventional ways. Some of these differences which represent
challenges to us include not keeping appropriate financial records,
inexperience with business contracts, not having access to
customary business banking or brokerage relationships, not having
quality manufacturing relationships, and not having customary
distribution arrangements.
In addition
to our cannabis-related business focus, we are also focusing on
cryptocurrencies, which each experience their own marketplace
volatility. Similar to the cannabis market, the cryptocurrency
market has patchy adoption and may suffer reputational risks due to
the United States Securities and Exchange Commission rulings and
the public perception that cryptocurrencies may sometimes be
associated with illegal activities.
Any one of
these challenges, if not managed well, could materially adversely
impact our business.
Many
cannabis activities, products, and services still violate
law.
The legal
patchwork to which cannabis companies are subject is still evolving
and frequently uncertain. While we believe that anti-cannabis laws
are softening and that the trend is toward the legalization of
cannabis products, many states and the U.S. government still view
some or all cannabis activity as illegal. Notwithstanding this
uncertainty, we intend to do our best to engage in activities that
are unambiguously legal and to use what influence we have with our
affiliates for them to do the same. But we will not always have
control over those companies with whom we do business, and there is
a risk that we could suffer a substantial and material loss due to
routine legal prosecution. Similarly, many jurisdictions have
adopted so-called “zero tolerance” drug laws and laws prohibiting
the sale of what is considered drug paraphernalia. If our or our
affiliates’ activities related to cannabis activities, products,
and services are deemed to violate one or more federal or state
laws, we may be subject to civil and criminal penalties, including
fines, impounding of cannabis products, and seizure of our assets.
A company in which we invested suffered asset seizure which
included some equipment licensed by us that caused us to incur a
loss.
Our
business model is to partner with or acquire other
companies.
We do not
manufacture or sell products or services. Rather, we historically
sought to find businesses whose products, managers, technology, or
other factors we like and acquire or invest in those businesses.
There is no certainty that we will find suitable partners or that
we will be able to engage in transactions on advantageous terms
with partners we identify. There is also no certainty that we will
be able to consummate a transaction on favorable terms, or any
transaction at all, with any potential acquisitions. To date,
several of our acquisitions/investments have not turned out well
for us.
The
Federal Government’s attitude toward cannabis and cryptocurrency
could materially harm our business
Changes to
the Federal Government’s administration, the manner in which the
federal government regulates cannabis, including how it intends to
enforce laws prohibiting medical marijuana and recreational
cannabis use, and the United States Securities and Exchange
Commission rulings on the treatment of cryptocurrencies and initial
coin offerings could materially negatively affect our
business.
Many
of the people and entities with whom we work in the cannabis
industry are not used to engaging in other than normal course
business transactions.
Many of the
people and entities with whom we engage may not be used to
operating in business transactions in the normal course. Entities
and persons operating in the cannabis industry may be unaccustomed
to entering into written agreements or keeping financial records
according to GAAP. Additionally, entities and persons with whom we
engage may not pay particular attention to the obligations with
which they have agreed in written contracts. We have experienced
these differences with several different entities in which we have
invested or considered investing, including several entities which
failed to comply with contractual obligations, which led us into
litigation and other legal remedies.
Our
actual results could differ materially from those anticipated in
our forward-looking statements.
This Form
10-Q contains forward-looking statements within the meaning of the
federal securities laws that relate to future events or future
financial performance. When used in this report, you can identify
forward-looking statements by terminology such as “believes,”
“anticipates,” “seeks,” “looks,” “hopes,” “plans,” “predicts,”
“expects,” “estimates,” “intends,” “will,” “continue,” “may,”
“potential,” “should” and similar expressions. These statements are
only expressions of expectation. Our actual results could, and
likely will, differ materially from those anticipated in such
forward-looking statements as a result of many factors, including
those set forth above and elsewhere in this report and including
factors unanticipated by us and not included herein. Although we
believe that the expectations reflected in our forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance, or achievements. Neither we nor
any other person assumes responsibility for the accuracy and
completeness of these statements. Accordingly, we caution readers
not to place undue reliance on these statements. Where required by
applicable law, we will undertake to update any disclosures or
forward-looking statements.
If we
are unable to protect our intellectual property, our competitive
position would be adversely affected.
We and our
partners and subsidiaries intend to rely on patent protection,
trademark and copyright law, trade secret protection and
confidentiality agreements with our employees and others to protect
our intellectual property. Despite our precautions, unauthorized
third parties may copy our and our affiliates’ and partners’,
products and services or reverse engineer or obtain and use
information that we regard as proprietary. In addition, the laws of
some foreign countries do not protect proprietary rights to the
same extent as do the laws of the United States. Our means of
protecting our, and our affiliates’ and partners’ proprietary
rights may not be adequate, and third parties may infringe or
misappropriate our and our affiliates’ and partners’ patents,
copyrights, trademarks, and similar proprietary rights. If we, or
our affiliates and partners, fail to protect intellectual property
and proprietary rights, our business, financial condition, and
results of operations would suffer. We believe that neither we nor
our affiliates and partners infringe upon the proprietary rights of
any third party, and no third party has asserted an infringement
claim against us. It is possible, however, that such a claim might
be asserted successfully against us in the future. We may be forced
to suspend our operations to pay significant amounts to defend our
rights, and a substantial amount of the attention of our management
may be diverted from our ongoing business, all of which would
materially adversely affect our business.
We
depend on our key personnel and may have difficulty attracting and
retaining the skilled staff and outside professionals we need to
execute our growth plans.
Our success
will be dependent largely upon the personal efforts of our Chief
Executive Officer, Chet Billingsley. The loss of key staff could
have a material adverse effect on our business and prospects.
Currently, we have two full-time employees, and we rely on the
services provided by outside professionals. To execute our plans,
we will have to retain our current employees and work with outside
professionals that we believe will help us achieve our goals.
Competition for recruiting and retaining highly skilled employees
with accounting, technical, management, marketing, sales, product
development, and other specialized training is intense. We may not
be successful in employing and retaining such qualified personnel.
Specifically, we may experience increased costs in order to retain
skilled employees. If we are unable to retain experienced employees
as needed, we would be unable to execute our business
plan.
Founder and CEO
Chet Billingsley, along with other members of the Company Board of
Directors, have considerable control over the company through their
aggregate ownership of 16.87% of the outstanding shares of the
Company’s Common Stock on a fully diluted basis.
As of
November 15, 2021, Mr. Billingsley owned approximately 11.00% of
the outstanding shares of the Company’s Common Stock on a fully
diluted basis. Together with other members of the Company’s Board
of Directors, management of the Company owns approximately 16.87%
of the outstanding shares of the Company’s Common Stock on a fully
diluted basis. Mr. Billingsley also holds 2,050,228 Series D
warrants, exercisable at $1.60 per share, and 87,456 Series B
warrants, exercisable at $0.11 per share. Additionally, Robert
Meyer, David Carlile, and Lori Stansfield, directors of the
Company, hold an aggregate of 631,455 Series D warrants exercisable
at $1.60 per share. Due to the large number of shares of Common
Stock owned by Mr. Billingsley and the directors of the Company,
management has considerable ability to exercise control over the
Company and matters submitted for shareholder approval, including
the election of directors and approval of any merger, consolidation
or sale of substantially all of the assets of the Company.
Additionally, due to his position as CEO and Chairman of the Board,
Mr. Billingsley has the ability to control the management and
affairs of the Company. The Company’s directors and Mr. Billingsley
owe a fiduciary duty to our shareholders and must act in good faith
in a manner each reasonably believes to be in the best interests of
our shareholders. As shareholders, Mr. Billingsley and the other
directors are entitled to vote their shares in their own interests,
which may not always be in the interests of our shareholders
generally.
We
face rapid change.
The market
for our partners’ and subsidiaries’ products and services is
characterized by rapidly changing laws and technologies, marketing
efforts, and extensive research, and the introduction of new
products and services. We believe that our future success will
depend in part upon our ability to continue to invest in companies
that develop and enhance products and services offered in the
cryptocurrency, energy, mining and minerals, technology, consumer
products, management services, manufacturing, or cannabis markets.
As a result, we expect to continue to make investments in our
partners and subsidiaries to promote further engineering, research,
and development. There can be no assurance that our partners and
subsidiaries will be able to develop and introduce new products and
services or enhance initial products in a timely manner to satisfy
customer needs, achieve market acceptance or address technological
changes in our target markets. Failure to develop products and
services and introduce them successfully and in a timely manner
could adversely affect our competitive position, financial
condition, and results of operations.
If we
experience rapid growth, we will need to manage such growth
well.
We may
experience substantial growth in the size of our staff and the
scope of our operations, resulting in increased responsibilities
for management. To manage this possible growth effectively, we will
need to continue to improve our operational, financial and
management information systems, will possibly need to create
departments that do not now exist, and hire, train, motivate and
manage a growing number of staff. Due to a competitive employment
environment for qualified accounting, technical, marketing, and
sales personnel, we expect to experience difficulty in filling our
needs for qualified personnel. There can be no assurance that we
will be able to effectively achieve or manage any future growth,
and our failure to do so could delay product development cycles and
market penetration or otherwise have a material adverse effect on
our financial condition and results of operations.
We
could face product liability risks and may not have adequate
insurance.
Our
partners’ and affiliates’ products may be used for medical
purposes. We may become the subject of litigation alleging that our
partners’ and affiliates’ products were ineffective or unsafe.
Thus, we may become the target of lawsuits from injured or
disgruntled customers or other users. We intend to, but do not now,
carry product and liability insurance, but in the event that we are
required to defend more than a few such actions, or in the event we
are found liable in connection with such an action, our business
and operations may be severely and materially adversely
affected.
There
is a limited market for our Common Stock.
Our Common
Stock is not listed on any exchange and trades on the OTC Markets
OTCQB system. As such, the market for our Common Stock is limited
and is not regulated by the rules and regulations of any exchange.
Freely trading shares of even fully reporting cannabis companies
receive careful scrutiny by brokers who may require legal opinion
letters, proof of consideration, medallion guarantees, or expensive
fee payments before accepting or declining share deposit. Through
association with cannabis companies and products, we have been
subject to heightened scrutiny by brokers in the past which may
make it difficult for current shareholders to sell or interested
investors from purchasing our shares of common stock. Further, the
price of our Common Stock and its volume in the market may be
subject to wide fluctuations. Our stock price could decline
regardless of our actual operating performance, and stockholders
could lose a substantial part of their investment as a result of
industry or market-based fluctuations. Our stock may trade
relatively thinly. If a more active public market for our stock is
not sustained, it may be difficult for stockholders to sell shares
of our Common Stock. Because we do not anticipate paying cash
dividends on our Common Stock for the foreseeable future,
stockholders will not be able to receive a return on their shares
unless they are able to sell them. The market price of our Common
Stock will likely fluctuate in response to a number of factors,
including but not limited to, the following:
|
● |
sales, sales
cycle, and market acceptance or rejection of our affiliates’
products; |
|
● |
our ability
to engage with partners who are successful in selling
products; |
|
● |
economic
conditions within the cannabis industry; |
|
● |
development
of law related to cannabis products and services; |
|
● |
the timing
of announcements by us or our competitors of significant products,
contracts or acquisitions or publicity regarding actual or
potential results or performance thereof; |
|
● |
domestic and
international economic, business and political
conditions; |
|
● |
justified or
unjustified adverse publicity; and |
|
● |
proper or
improper third-party short sales or other manipulation of our
stock. |
We
have a long business and corporate existence.
We began in
Silicon Valley in 1985 as a limited partnership and operated as
Mentor Capital, LP until we incorporated as Main Street Athletic
Clubs, Inc. in California in 1994. We were privately owned until
September 1996; our Common Stock began trading on the Over The
Counter Pink Sheets on March 12, 1997. Our merger and acquisition
and business development activities have spanned many business
sectors, and we went through a bankruptcy reorganization in 1998.
In late 2015, we reincorporated under the laws of the State of
Delaware. We currently focus our investment efforts on a wide
variety of sectors, some of which are new to us and with which we
have limited experience.
Failure to
maintain effective internal controls in accordance with Section 404
of the Sarbanes-Oxley Act of 2002 could have a material adverse
effect on our stock price.
Section 404
of the Sarbanes-Oxley Act of 2002 and the related rules and
regulations of the SEC require annual management assessments of the
effectiveness of our internal control over financial reporting. If
we fail to adequately maintain compliance with, or maintain the
adequacy of, our internal control over financial reporting, as such
standards are modified, supplemented or amended from time to time,
we may not be able to ensure that we can conclude on an ongoing
basis that we have effective internal control over financial
reporting in accordance with Section 404 of the Sarbanes-Oxley Act
of 2002 and the related rules and regulations of the SEC. If we
cannot favorably assess our internal controls over financial
reporting, investor confidence in the reliability of our financial
reports may be adversely affected, which could have a material
adverse effect on our stock price.
We
have indemnified our officers and directors.
We have
indemnified our Officers and Directors against possible monetary
liability to the maximum extent permitted under California and
Delaware law. The managers of Mentor Partner I, LLC and Mentor
Partner II, LLC have been indemnified to the maximum extent
permitted under California and Texas law.
The
worldwide economy could impact the company in numerous
ways.
The effects
of negative worldwide economic events, such as the continuing
coronavirus outbreak, product and labor shortages, and a global
economic slowdown may cause disruptions and extreme volatility in
global financial markets, increased rates of default and
bankruptcy, impact levels of consumer spending, and may impact our
business, operating results, or financial condition. The ongoing
worldwide economic situation, future weakness in the credit
markets, and significant liquidity problems for the financial
services industry may also impact our financial condition in a
number of ways. For example, current or potential customers may
delay or decrease spending with us, or our partners and affiliates,
or may not pay us, or our partners or affiliates, or may delay
paying us, or our partners or affiliates, for previously purchased
products and services. Also, we may have difficulties in securing
additional financing.
Competitors
in the Canadian public market may have a material advantage over
us. The Canadian government has loosened the laws and regulations
with regard to cannabis earlier and at a faster pace than in the
United States. The financial regulations with regard to cannabis
investing and banking are also more favorable in Canada than for
the Company in the United States. This Canadian advantage may have
a material negative effect on the Company’s business.
Item 2. Unregistered Sales of
Equity Securities and Use of Proceeds.
On May 30,
2018, Mentor sold 11 shares of its unregistered Series Q Preferred
Stock in a private placement for $110,000.
Other than
as stated above, there have been no other unregistered securities
sold within the past three years.
Item 3. Defaults Upon Senior
Securities and Use of Proceeds.
None.
Item 4. Mine Safety
Disclosures.
None.
Item 5. Other
Information.
None.
Item 6. Exhibits.
The
following exhibits are filed as part of this report:
Exhibit
Number |
|
Description |
3.1 |
|
Amended and Restated Certificate of
Incorporation of the Company (Incorporated by reference to Mentor’s
Definitive Information Statement on Schedule 14C filed with the SEC
on July 10, 2015). |
3.2 |
|
Bylaws of the Company (Incorporated
by reference to Mentor’s Definitive Information Statement on
Schedule 14C filed with the SEC on July 10, 2015). |
4.1 |
|
Instrument Defining Rights of
Security Holders. (A copy of our Bankruptcy Plan of Reorganization,
including Mentor’s Sixth Amended Disclosure Statement, incorporated
by reference to Exhibit 4 of our Registration Statement on Form 10,
filed with the SEC on November 19, 2014.) |
4.2 |
|
Description of assumed warrants to
purchase shares of Mentor’s Common Stock (Incorporated by reference
to Mentor’s Definitive Information Statement on Schedule 14C filed
with the SEC on July 10, 2015). |
4.3 |
|
Certificate of Designations of
Rights, Preferences, Privileges and Restrictions of Series Q
Preferred Stock (Incorporated by reference to Exhibit 4.3 to
Mentor’s Quarterly Report on Form 10-Q for the Period Ended
September 30, 2017, filed with the SEC on November 9,
2017) |
31.1 |
|
Certification of the Chief Executive Officer required
by Rule 13a-14(a) of the Securities Exchange Act of 1934, as
amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002 |
31.2 |
|
Certification of the Principal Financial Officer
required by Rule 13a-14(a) of the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 |
32.1 |
|
Certification of the Chief Executive Officer pursuant
to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 |
32.2 |
|
Certification of the Principal Financial Officer
pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002 |
101 |
|
XBRL
Exhibits |
101.INS |
|
Inline XBRL
Instance Document |
101.SCH |
|
Inline XBRL
Taxonomy Extension Schema Document |
101.CAL |
|
Inline XBRL
Taxonomy Extension Calculation Linkbase Document |
101.DEF |
|
Inline XBRL
Taxonomy Extension Definition Linkbase Document |
101.LAB |
|
Inline XBRL
Taxonomy Extension Label Linkbase Document |
101.PRE |
|
Inline XBRL
Taxonomy Extension Presentation Linkbase Document |
104 |
|
Cover Page
Interactive Data File (embedded within the Inline XBRL
document) |
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
Mentor
Capital, Inc. |
|
|
|
Date: November 12,
2021 |
By: |
/s/ Chet
Billingsley |
|
|
Chet Billingsley, Chief
Executive Officer |
|
|
|
Date: November 12,
2021 |
By: |
/s/ Chet
Billingsley |
|
|
Chet Billingsley,
Principal Financial Officer |
Mentor Capital (QB) (USOTC:MNTR)
Historical Stock Chart
From Apr 2022 to May 2022
Mentor Capital (QB) (USOTC:MNTR)
Historical Stock Chart
From May 2021 to May 2022